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Abstract 
The enzyme telomerase plays an important role in cell immortalization and 
hence cancer development. It can be detected in most kinds of tumors but is 
not expressed in the majority of healthy cells. Therefore, telomerase inhibition 
appears to be a promising approach for a specific cancer therapy with 
reduced side effects. 
The work presented here concentrated on the treatment of non-small cell lung 
cancer by telomerase inhibition and can be divided into three parts: 
1. Characterization of the G-quadruplex stabilizing substance BRACO19 
under biopharmaceutical and stability aspects. BRACO19 showed a poor 
permeability across biological barriers and was instable under 
physiological conditions. 
2. Evaluation of cationic chitosan/PLGA nanoparticles as a carrier system for 
2’-O-Methyl-RNA antisense oligonucleotides (2OMR), which was directed 
against the template region of the telomerase specific RNA hTR. The 
chitosan content in the particles considerably influenced the uptake 
improvement of 2OMR into cells. Despite a poor complex stability in 
physiological media a successful inhibition of telomerase activity in lung 
cancer cells could be achieved. 
3. Targeted delivery of anti-telomerase siRNA to CD44-overexpressing lung 
cancer cells using hyaluronic acid modified DOTAP/DOPE liposomes. 
These liposomes efficiently bound siRNA, protected it from degradation by 
nucleases and increased its uptake into CD44-overexpressing lung cancer 
cells. The modification improved the colloidal stability of lipoplexes in cell 
culture medium and their cytotoxicity. 
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Kurzzusammenfassung 
Das Enzym Telomerase spielt eine wichtige Rolle bei der Immortalisierung 
von Zellen und damit auch bei der Entwicklung von Krebserkrankungen. Es 
wird in einer Vielzahl von Tumoren exprimiert, jedoch nicht in den meisten 
gesunden Zelltypen. Durch seine Hemmung erhofft man sich eine sehr 
spezifische und nebenwirkungsarme Krebstherapie. 
Die durchgeführten Arbeiten konzentrierten sich auf die Behandlung von 
nicht-kleinzelligen Lungenkrebs mittels Telomeraseinhibitoren und unterteilen 
sich in drei Teile: 
1. Charakterisierung des G-Quadruplex stabilisierenden Wirkstoffs 
BRACO19 unter biopharmazeutischen und stabilitätsrelevanten Aspekten. 
BRACO19 permeierte schlecht über biologische Barrieren und war unter 
physiologischen Bedingungen instabil. 
2. Evaluierung von kationischen Chitosan/PLGA-Nanopartikeln als 
Trägersystem für ein gegen die Template Region der Telomerase-
spezifischen RNA hTR gerichtetes 2’-O-Methyl-RNA Antisense 
Oligonukelotid. Der Chitosangehalt der Partikel beeinflusste die 
Aufahmeverbesserung von 2OMR in Zellen deutlich. Trotz geringer 
Komplexstabilität in physiologischen Medien konnte das Enzym 
Telomerase in Lungenkrebszellen effizient gehemmt werden. 
3. Targeted Delivery von Anti-Telomerase siRNA mit Hilfe von 
Hyaluronsäure-modifizierten kationischen DOTAP/DOPE Liposomen in 
CD44-überexprimierende Lungenkrebszellen. Diese Liposomen konnten 
effizient die siRNA binden, gegen Abbau durch Nucleasen schützen und 
steigerten ihre Aufnahme in CD44-überexprimierende Lungenkrebszellen. 
Weiterhin verbesserte die Modifizierung die kolloidale Stabilität der 
Lipoplexe in Zellkulturmedium sowie deren Zytotoxizität. 
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Chapter 1  
General Introduction 
1.1 Lung Cancer 
Together with cancers of the genital and digestive systems, lung cancer is the 
most prominent type of malignancies in Germany and the United States [1, 2]. 
In contrast to these other kinds of cancer, it still has a very poor prognosis. It 
is the leading cause for cancer related deaths and the overall five-year 
survival rate is only 15 – 20%. Therefore it is considered as one of the most 
malignant kind of cancers. The reason for this poor prognosis is mostly due to 
the advanced stage of tumors at the time of discovery. Smoking, both active 
or passive, is the major cause for the development of lung cancer while other 
factors like exposure to the radioactive gas radon, carcinogenic substances or 
fibers like asbestos play a minor role. 
Histologically lung cancers are divided into several subtypes. For treatment 
purposes, the majority of malignancies are roughly classified as small cell 
lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC accounts 
for approximately 20% of lung cancers and can be considered a class of its 
own. The term NSCLC comprises most other types of lung cancer, which are 
according to the World Health Organization (WHO) [3]: 
• squamous cell carcinoma 
• adenocarcinoma 
• large cell carcinoma 
• adenosquamous carcinoma 
• sarcomatoid carcinoma 
• carcinoid tumors 
• salivary gland tumors. 
These classes are further subdivided for more specific categorization. 
 
For treatment, an assessment of the progress of the disease is important for 
the choice of a suitable therapy. This procedure is called “staging”.  
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Diagnostic methods are x-ray radiography, which has a very low sensitivity, 
computed tomography (CT), positron emission tomography (PET) or magnetic 
resonance imaging (MRI). These are noninvasive methods for the detection 
and localization of malignant lesions. For the correct classification biopsies 
from the tumors are required. They are obtained by endoscopic methods such 
as brochoscopy, mediastinoscopy or thoracoscopy or after surgical 
intervention. 
Patient with SCLC are categorized as having either limited disease (LD) or 
extensive disease (ED), which depends on the spread of the tumor to distant 
sites [4]. LD tumors are confined to the ipsilateral hemitorax while ED tumors 
include malignant pleural or pericardial effusions or hematogenous 
metastases. Since most SCLC tumors are not resectable and already formed 
metastases at the time of discovery, chemotherapy and radiotherapy are the 
treatments of choice for SCLC. 
Staging of NSCLC is more complex. For this large group the so-called TNM 
staging system, which has been developed by the Union International Contre 
le Cancer (UICC; International Union Against Cancer; http://www.uicc.org/) 
and American Joint Committee on Cancer (AJCC; 
http://www.cancerstaging.org/), is applied to provide a description for the 
status of the disease. In this system T describes the extent of the primary 
tumor (T0 – T4), N the involvement of regional lymph nodes (N0 – N3) and M 
the absence (M0) or presence (M1) of distant metastasis. Using these 
descriptors, NSCLC is then classified into four stages I – IV, where stages I to 
III are further subdivided in A and B [5, 6]. Figure 1-1 gives an overview of the 
staging system and the relevant criteria (adopted from Lababede et al. [7]).  
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Figure 1-1: TNM staging system of non-small cell lung cancer (NSCLC) according to 
Union International Contre le Cancer and American Joint Committee on Cancer. The 
figure was adopted from Lababede et al. [7]. T = extent of the primary tumor (T0 – T4), 
N = involvement of regional lymph nodes (N0 - N3) and M = absence (M0) or presence 
(M1) of distant metastasis 
 
Unfortunately, most patients are diagnosed at the late stages III and IV where 
the 5-year survival rates are only minimal. The low probability of early 
detection is due to the fact that symptoms for lung cancer like cough, 
dyspnea, weight loss or chest pain are not very specific and therefore might 
be attributed to other diseases. 
Table 1-1 gives an overview on the chance of discovery at a certain stage and 
the 5-year survival rates [8, 9]. 
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Table 1-1: Percentages of patients diagnosed with non-small cell lung cancer at a 
certain stage according to the TNM classification system and the average 5-year 
survival rates [8, 9]. 
Diagnosis Survival 
Stage 
Patients diagnosed with lung 
cancer at this stage Stage 
5-year 
survival rate 
I 25% I A 75 – 80% 
  I B 55 – 60% 
II 7% II A 55 – 60% 
  II B 35 – 45% 
III 32% III A 30 – 40% 
(T3, N1, M0) 
15% 
(T1-3, N2, M0) 
  III B 5% 
IV 36% IV < 1% 
 
Based on the staging results the appropriate treatment for NSCLC is chosen. 
The commonly used options are surgery, radiotherapy and chemotherapy. 
Depending on the disease status they can be used either alone or in 
combination. 
For Patients that were diagnosed as stage I or stage II, surgery is the initial 
treatment of choice because the disease is still confined to a certain region of 
the lung. Surgery can be done as: 
• segmentectomy or wedge resection, where only parts of a lobe are 
removed. 
• lobectomy, where an entire lobe is removed. 
• pneumonectomy, where the entire lung is removed. 
Patients that are inoperable because of the tumor localization or their overall 
poor health and performance status are treated by radiotherapy. 
The choice for the correct treatment of patients diagnosed stage III is more 
difficult because this class is very heterogeneous. At stage III A, if no 
mediastinal lymph nodes are involved, the treatment is comparable to the one 
for stage II.  If ipsilateral lymph nodes are afflicted a multimodal strategy 
consisting of surgery and chemotherapy or radiotherapy and chemotherapy is 
employed. In this case patients might benefit from neoadjuvant chemotherapy 
prior to the treatment. 
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Lung cancers at stage III B with contralateral involvement of lymph nodes are 
considered as being unresectable.  Therefore, chemoradiation is the 
treatment of choice. If the tumor spread can be reduced by this therapy, 
surgery might follow the initial treatment. Stage III B tumors with malignant 
pleural effusions are treated as being M1 and hence the same therapeutic 
conditions as for stage IV tumors apply. 
As can be seen from Table 1-1 the prognosis for patients with metastatic 
tumors (stage IV) is extremely poor. Since patients are considered as being 
incurable a palliative chemotherapy and/or radiotherapy are applied to relieve 
pain and other distressing symptoms and improve the patient’s quality of life. 
After initial therapy an adjuvant chemotherapy or radiotherapy or 
chemoradiation often continues the treatment to eradicate remaining 
cancerous cells. 
Table 1-2 gives an overview on the drugs that are currently used for 
chemotherapy. Usually, a platin-based drug is given in combination with 
another cytostatic agent. New and promising substances are epidermal 
growth factor receptor tyrosine kinase inhibitors and the angiogenesis inhibitor 
Bevacizumab, a monoclonal antibody that is directed against the vascular 
endothelial growth factor. 
Table 1-2: Chemotherapeutic agents currently used for the treatment of NSCLC and 
their mode of action. 
Mechanism Drugs 
Platin-based DNA-crosslinker Cisplatin 
 Carboplatin 
Mitotic inhibitors Paclitaxel 
 Docetaxel 
 Vinorelbine 
 Vinblastine 
Antimetabolites Gemcitabine 
 Pemetrexed 
Topoisomerase inhibitors Etoposide 
 Irinotecan 
Antitumor antibiotics Mitomycin C 
Alkylating agents Ifosfamide 
Epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors 
Gefitinib 
Erlotinib 
Vascular endothelial growth factor (VEGF) inhibitors Bevacizumab 
 
Chapter 1 – General Introduction 
   
 6 
All these therapeutic agents are administered systemically resulting in more or 
less severe unwanted side effects. The most prominent are nausea and 
vomiting, diarrhea or obstipation, pain, fatigue, reduction of red and white 
blood cells due to bone marrow depression or hair loss.  
To circumvent such problems, regional drug delivery to the lungs via 
aerosolized chemotherapy has been suggested. This route of administration 
not only reduces the systemic burden but also avoids hepatic first-pass 
metabolism and allows the deposition of higher drug levels at the site of 
interest. Tatsumura et al. reported a high local deposition of 5-Fluorouracil 
after inhalation and very low systemic drug concentrations while obtaining a 
good anti-tumor response [10, 11]. Similar results were obtained in other 
studies with e.g. aerosolized doxorubicine [12], cisplatin [13] or 9-nitro-20(s)-
camptothecin [14]. However, inhalative therapy is not yet established as a 
standard treatment because the effect of high doses of chemotherapeutics 
administered locally to the lung tissue still has to be evaluated to avoid 
pulmonary toxicity and drug-induced lung diseases. Therefore, further studies 
on new anti-cancer agents and drug formulations are needed to help this 
promising therapeutic approach reach the clinics. 
An interesting target for new anti-cancer agents is the enzyme telomerase, 
which plays an important role in cell immortalization and hence cancer 
development (see section 1.2). Telomerase has been found to be upregulated 
in about 85% of lung cancers and its expression correlated with a poor 
prognosis for NSCLC patients [15-18]. 
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1.2 Telomeres, Telomerase and their Implication in Cancer 
Development 
In 1961 Hayflick and Moorehead demonstrated that human skin fibroblast in 
culture could only undergo a limited number of about 40 to 50 cell divisions 
before they entered the state of cellular senescence [19]. Furthermore, in 
1965 Hayflick also reported a lower number of divisions for cells in culture 
derived from older people than for cells from younger people [20]. He 
suggested that this “countdown for senescence” is initiated at birth. Harley et 
al. demonstrated in 1990 that the length of chromosomal ends, the telomeres, 
shortens during aging of human fibroblasts [21]. The connection between 
telomere shortening and cellular senescence and/or apoptosis was shown 
after the discovery of the enzyme telomerase [22], a ribonucleoprotein that 
maintains the chromosomal ends. Ectopic expression of the catalytic subunit 
of this enzyme resulted in the elongation of telomeres and significantly 
extended the life span of human primary cells [23, 24]. 
 
Telomeres are non-coding guanine-rich repetitive sequences that end in a 
single-stranded 3’-overhang [25]. Humans telomeres are tandem repeats of 
the hexameric sequence 5’-(TTAGGG)-3’, which is highly conserved in higher 
eukaryotes [26] (Figure 1-2). Due to their special structure, telomeres protect 
chromosomal ends from being recognized as damaged DNA. This prevents 
the initiation of such events like non-homologous end joining or homology 
directed repair, two mechanisms that strongly compromise the integrity of 
chromosomal ends. To fulfill their protective function, telomeres form a lasso-
like structure, the so-called t-loop [27]. For the t-loop formation the G-rich 
single strand 3’-overhang invades the double stranded region of telomeres to 
form base pairs with the C-rich strand, thereby displacing the G-strand 
(d-loop; Figure 1-2). 
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Figure 1-2: Location and structure of telomeres. Telomeres are repetitive hexameric 
sequences at the extremities of chromosomes that end in a 3’-guanine-rich overhang. 
This overhang can invade the double-stranded region to form the so-called t-loop. 
 
Telomeres are stabilized by a telomere-specific six-protein-complex termed 
shelterin (reviewed in [28]). The proteins telomeric repeat binding factor 1 and 
2 (TFR1 and TRF2) bind to the double-stranded part of telomeres while 
protection of telomeres 1 (POT1) binds the single-stranded overhang. The 
other components TRF1-interacting factor 2 (TIN2), TIN2 and POT1-
interacting protein 1 (TPP1) and transcriptional repressor/activator protein 1 
(Rap1) do not directly bind the telomeres but are associated with TRF1, TRF2 
and POT1. This protein complex is essential for the integrity of telomeres, 
their size regulation and also for the recruitment of other proteins necessary 
for DNA repair and replication, DNA damage signaling and chromatin 
structure.  
In normal somatic cells telomeres shorten during each cell cycle by about 
50 – 100 bp because of the end replication problem [29], i.e. the inability of 
DNA polymerase to fully replicate the lagging strand during DNA replication, 
and a post-replicative processing of the 5’-strand [30]. At birth telomeres are 
about 8 – 12 kb in length and normal cells show a total lifetime loss of about 
2 – 4 kb [31]. Other cell types like stem cells of renewal tissue show a 
reduced rate of telomere erosion and germ cells and fetal tissue can maintain 
their telomere length at 15 – 20 kb [32].  
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Critically short telomeres are identified as damaged DNA most probably 
because of insufficient protection by shelterin proteins. They are recognized 
by the two phosphatidyinositol-3-kinase related protein kinases, ATM and 
ATR. This recognition triggers a molecular mechanism that results in the 
activation of p53, RB and p21. As a consequence cell cycle progression is 
inhibited and cells enter the state of senescence or even undergo apoptosis 
(reviewed by [28, 31]). Telomere erosion alone can also serve as a 
p53-independent checkpoint for cell proliferation. Cells that continue dividing 
will face serious chromosomal damages that finally result in cell death. This 
second checkpoint is termed “crisis” (Figure 1-3). 
However, in the absence of functional tumor suppressors and after activation 
of oncogenes like c-Myc because of the genomic instabilities and 
rearrangements, cancer cells can escape these cell cycle checkpoints by 
expressing the enzyme telomerase [31, 33, 34]. Telomerase is a 
ribonucleoprotein complex that synthesizes new TTAGGG-sequences at the 
3’-ends of chromosomes to maintain telomeres at a stable length. It is 
composed of human telomerase RNA (hTR) [35], which contains the template 
region for the synthesis of new telomeric repeats, and human telomerase 
reverse transcriptase (hTERT), the catalytic subunit of the enzyme (Figure 
1-4) [36]. In the active complex two hTR/hTERT units are associated with one 
dyskerin molecule [37]. 
Telomerase is normally expressed at high levels during embryonic 
development but is downregulated after birth in the larger parts of tissues. In 
the healthy organism telomerase activity is limited to germ lines and certain 
stem cell compartments, i.e. specialized cells that need to retain their 
unlimited proliferative capacity [38, 39]. 
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Figure 1-3: M
echanism
 of cellular senescence and apoptosis and the influence of telom
erase expression on cell survival. In norm
al cells telom
eres 
shorten until they reach a critical length and becom
e dysfunctional. This triggers a m
echanism
 that results in cell cycle arrest, senescence and 
apoptosis. C
ells that do not stop dividing w
ill face serious chrom
osom
al dam
ages due to the loss of telom
eres. Few
 cells like stem
 cells, germ
 line 
cells or fetal cells express the enzym
e telom
erase and can therefore divide indefinitely. For cancer developm
ent the (re)activation of telom
erase is 
a crucial step tow
ard im
m
ortality. They norm
ally have very short telom
eres that constantly require telom
ere m
aintenance by telom
erase. 
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Telomerase has been reported to be active in about 80-90% of cancer cells 
[40, 41]. Its expression is a crucial step for their limitless replicative potential 
and evasion from apoptosis, which are two of the six hallmarks of cancer [42]. 
Those cancer cells that do not express telomerase maintain their telomeres 
by a homologous recombination-mediated process termed alternative 
lengthening of telomeres (ALT; reviewed in [43, 44]). 
 
 
Figure 1-4: Elongation of the 3’-strand overhang by telomerase. hTERT = human 
telomerase reverse transcriptase (the catalytic subunit); hTR = human telomerase RNA 
(contains the template region for the synthesis of new TTAGGG-repeats). 
 
Due to its crucial role in carcinogenesis the inhibition of telomerase became 
quickly an interesting target for the development of new anti-cancer 
strategies. It could be shown that telomerase inhibition results in telomere 
shortening and suppression of tumor growth both in vitro and in vivo. 
To date numerous strategies for telomerase inhibition, either directly or 
indirectly, have been investigated. The direct approaches targeted both the 
catalytic subunit hTERT and the RNA component hTR. Potent inhibitors of 
hTERT are the reverse transcriptase inhibitors BIBR 1532 [45] or AZT [46]. 
hTR could be successfully targeted with chemically modified oligonucleotides 
that block the template region for the synthesis of new telomeric repeats [47, 
48]. The lipid-linked oligonucleotide and telomerase template antagonist 
GRN163L [49-51] has entered several clinical trials to prove its efficacy either 
administered alone or in combination with established anti-cancer drugs 
(www.clinicaltrias.gov). 
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Another strategy does not focus on telomerase but on its substrates, the 
telomeres. Here the class of so-called G-quadruplex stabilizing substances 
has been widely investigated. G-quadruplexes are special structures that can 
form in guanine-rich DNA sequences like the telomeres. Their stabilization by 
specially designed molecules prevent telomerase from recognizing the single-
strand overhangs. Furthermore, G-quadruplex stabilizers were reported to 
induce telomere dysfunction due to the displacement of telomere-associated 
proteins such as the shelterin complex. Therefore, a treatment with this kind 
of inhibitors results in a faster response as could be expected from telomere 
erosion alone [52-54]. 
Vaccination against hTERT as a tumor antigen is another approach currently 
under investigation in clinical trials. Cancer patients are immunized against 
short hTERT peptide sequences that can be recognized by cytotoxic 
T-lymphocytes [55-57]. 
Other strategies employ adenoviral-mediated gene therapy. The gene 
constructs contain promoter regions for hTR or hTERT so that transcription of 
the actual gene sequence will only occur in telomerase expressing cells. This 
mechanism is currently exploited for suicide gene therapy [58, 59] and 
oncolytic viral therapy [60]. 
Concerns were raised that telomere inhibition might lead to severe side 
effects because other telomerase expressing cells, i.e. germ cells and stem 
cells, will also be affected by the treatment. However, telomeres from cancer 
cells are normally considerably shorter than those from other telomerase 
expressing cells [32]. Since cancer cells divide more rapidly, telomere erosion 
in tumors should be much faster. Therefore the effect of telomerase inhibition 
is expected to be much more pronounced in cancer cells than in other cell 
types. 
Another point of criticism in anti-telomerase therapy might be the lag time 
between the start of the treatment and first effects on cell proliferation. This 
period strongly depends on the initial telomere length of tumor cells. However, 
it has been demonstrated that telomerase inhibition enhances the efficacy of 
other anti-cancer therapies [61-66]. So even if telomerase inhibition alone 
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cannot be used because of a retarded effect this synergism might be 
exploited in future therapies. 
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1.3 Objectives of the studies 
This project was done in cooperation with the group of Professor Dr. Ulrich 
Klotz from the Dr. Margarete Fischer-Bosch Institute for Clinical 
Pharmacology, Stuttgart, and University of Tübingen and financially supported 
by the Deutsche Krebshilfe e.V. (Project no.: 10-2035-Kl I) and the Robert 
Bosch Foundation (Stuttgart, Germany). 
The work described in Chapter 6 was done in the group of Professor Dr. Elias 
Fattal, UMR CNRS 8612, Pharmaceutical Faculty of the University Paris Sud 
11, Châtenay-Malabry, France, and financially supported by the GALENOS 
Fellowship in the Framework of the EU Project "Towards a European PhD in 
Advanced Drug Delivery, Marie Curie Contract MEST-CT-2004-404992. 
The aim of the project was the development of new strategies for the 
treatment of non-small lung cancer by telomerase inhibition with formulations 
that are suitable for a local application via the inhalative route.  
For this purpose different telomerase inhibitors that have been described in 
the literature were tested. From these studies three substances were selected 
as potential drug candidates: 
• the acridine derivative BRACO19, which belongs to the telomere-targetig 
G-quadruplex stabilizing substances [67]. 
• an antisense 2’-O-methyl-RNA (2OMR) that is complementary to the 
template region of hTR [48]. 
• a small interfering RNA (siRNA) that is directed against the mRNA of the 
catalytic subunit hTERT. 
 
BRACO19 (Figure 1-5) could be regarded as the prototype of a new class of 
drugs based on 3,6,9-substituted acridine derivatives. Although it has been 
reported to be a very potent telomerase inhibitor and effective in targeting the 
telomeres, nothing was known about its biopharmaceutical and physico-
chemical properties. Since these information are essential for the 
development of delivery strategies, the studies with BRACO19 concentrated 
on a thorough characterization regarding its transport across biological 
barriers and stability under physiological conditions and a categorization 
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according to the biopharmaceutical classification system (BCS) as introduced 
by Amidon et al. [68] (Figure 1-6; Chapter 2 and Chapter 3). 
 
 
Figure 1-5: Structure of the 3,6,9-substituted acridine derivative BRACO19 
 
 
Figure 1-6: The categorization of drug compounds according to the biopharmaceutical 
classification system. The key factors are the dissolution of the drug in biological 
fluids and its permeation accros biological barriers. 
 
The oligonucleotide-based drugs 2OMR and siRNA are known to be very 
effective and specific. However, due to their size and negative charge the 
main obstacle for these molecules is their poor uptake into cells. Furthermore, 
they are rapidly degraded in the presence of nucleases. Therefore, this kind of 
drugs requires a suitable carrier system to ensure an efficient and safe 
uptake. 
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For 2OMR a delivery system based on cationic chitosan/PLGA nanoparticles 
was chosen. Chitosan and PLGA (Figure 1-7) are both biocompatible and 
biodegradable. 
 
 
Figure 1-7: Structures of the polyester poly(lactic-co-glycolic acid) (PLGA) and the 
polysaccharide chitosan which is composed of randomly distributed β-(1-4)-linked 
D-glucoseamine and N-acetyl-D-glucoseamine. 
 
Nanoparticles composed of these polymers were previously developed for the 
delivery of plasmid DNA. In our studies they were evaluated as carriers for the 
short oligonucleotides 2OMR. The work focused on the influence of chitosan 
content in the particle formulation on binding and delivery efficiency and the 
fate of nanoplexes in different cell types as well as the efficacy regarding the 
inhibition of telomerase activity (Chapter 4 and Chapter 5). 
RNA interference (RNAi) is the latest mechanism described for gene 
silencing. RNAi is mediated via short double stranded RNA sequences with a 
length of normally 21 base pairs and overhanging 3’-ends [69, 70] termed 
short inhibitory RNA (siRNA). After its discovery, it became rapidly a powerful 
tool in molecular biology for studying the downregulation of gene expression. 
These properties made it also interesting for medical applications. 
For the delivery of siRNA a more refined system based on cationic 
DOTAP/DOPE liposomes was investigated. These liposomes were modified 
with the endogenous glycosaminoglycan hyaluronic acid (Figure 1-8) for the 
targeting of cancer cells that overexpress the CD44-receptor. 
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Figure 1-8: Structures of the lipids DOTAP (1,2-dioleoyl-3-trimethylammonium-
propane) and DOPE (1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) and the 
endogenous polymer hyaluronic acid. 
 
In these studies the influence of the modification on liposome properties was 
examined in comparison with non-modified liposomes. Special attention was 
given to the liposome properties, binding and protection of siRNA in the 
complex, the cytotoxicity of the new system and its efficiency for targeting 
CD44-expressing lung cancer cells (Chapter 6). 
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Chapter 2  
Biopharmaceutical Characterization of the 
Telomerase Inhibitor BRACO19 
 
 
 
 
 
 
 
 
 
 
The data presented in this chapter has been published as a short 
communication in the journal Pharmaceutical Research: 
 
Taetz, S., Baldes, C., Mürdter, T. E., Kleideiter, E., Piotrowska, K., Bock, U., 
Haltner-Ukomadu, E., Mueller, J., Huwer, H., Schaefer, U. F., Klotz, U., 
Lehr, C.-M. 
Biopharmaceutical characterization of the telomerase inhibitor BRACO19. 
(2006) Pharm. Res., 23(5), 1031-1037. 
 
DOI: 
10.1007/s11095-006-0026-y 
 
Weblink: 
http://www.springerlink.com/content/w06750366765q138/ 
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2.1 Introduction 
Telomerase, a ribonucleoprotein enzyme that belongs to the class of reverse 
transcriptases, plays an important role in the control of proliferation and 
carcinogenesis by maintaining the length of telomeres. Telomeres are lasso- 
like structures at the end of chromosomes. They protect them from 
recombination, nuclease degradation, DNA repair mechanisms and end-to-
end fusions. They also act as a kind of “mitotic clock” by constant erosion 
after each cell cycle. Reaching a critical length is a signal for the cell to stop 
dividing and enter the state of replicative senescence (M1 stage). Cells that 
bypass replicative senescence and continue dividing will face serious DNA 
damages and subsequently cell death due to further telomere shortening 
(M2 stage or crisis). However, cells expressing high levels of telomerase, like 
cancer cells, can escape this mechanism by keeping the telomere length 
above this limit and therefore divide indefinitely [71, 72]. 
The approach of telomerase inhibition for the treatment of cancer attracted 
increasing interest in the last years because telomerase is expressed in most 
types of cancer cells but not in normal cells with the exception of 
hematopoetic stem cells, germ cells, stem cells of the intestine and the skin. 
Non- small cell lung cancer (NSCLC) is the most common form of lung cancer 
and has a poor prognosis. Misawa et al. showed that telomerase inhibition in 
the NSCLC cell line A549 led to an increase in apoptosis and higher 
sensitivity to chemotherapeutic agents [64]. Inhibiting telomerase with suitable 
drugs would ideally affect cancer cells only and spare healthy tissue. Due to 
such inherent selectivity an inhalative application of telomerase inhibitors 
might be possible. The drug could be delivered directly to the lung, thereby 
further reducing unwanted systemic drug effects. 
A screening for potential telomerase inhibitors led us to the acridine derivative 
BRACO19 (9- [4- (N,N- dimethylamino)phenylamino]- 3,6- bis(3- pyrrolodino-
propionamido) acridine x 3HCl; Figure 2-1) [73]. This substance inhibits 
telomerase activity and can lead to telomere dysfunction by G- quadruplex 
stabilization in telomeres [67, 74]. 
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Figure 2-1: The 3,6,9- substituted acridine derivative BRACO19 (9-[4-(N,N-
dimethylamino)phenylamino]-3,6-bis(3-pyrrolodinopropionamido) acridine x 3HCl) 
according to [67]. 
 
For the development of a new drug formulation knowledge about 
biopharmaceutical properties like solubility, cytotoxicity, permeation of the 
drug across biological barriers (like the lung epithelia) or protein binding are 
as important as the cytotoxic or pharmacological properties of the drug.  
Protein binding and interaction with membrane lipids were tested by two 
HPLC methods using immobilized human serum albumin (HSA) and 
immobilized artificial membrane (IAM) chromatography, respectively. 
To investigate the permeability of BRACO19 across relevant biological 
barriers we used the SV40 virus immortalized cell line 16HBE14o- [75, 76] 
and the adenocarcinoma cell line Calu-3 [77, 78] as models of the bronchial 
epithelium. The alveolar epithelium was represented by primary human 
alveolar type II cells which develop type I characteristics when cultivated 
under appropriate conditions [79, 80]. For comparison we also included the 
intestinal adenocarcinoma cell line Caco-2, an established model for intestinal 
drug absorption [81]. 
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2.2 Materials and Methods 
2.2.1 Substances and buffers 
BRACO19 was synthesized by ENDOTHERM GmbH (Saarbruecken, 
Germany) according to Harrison et al. [82]. Identity was proven by NMR, 
purity by HPLC. Propranolol- HCl was purchased from Synopharm GmbH & 
Co. KG (Barsbuettel, Germany), cyclosporin A from Calbiochem® (Merck 
Bioscience GmbH, Bad Soden, Germany), fluorescein- Na and 
tetraethylammonium chloride (TEAC) were obtained from Fluka Chemie 
GmbH (Buchs, Switzerland).  
HBSS (Hank’s balanced salt solution) buffer was composed of 137.0 mM 
NaCl, 5.36 mM KCl, 4.26 mM NaHCO3, 0.18 mM Na2HPO4 x 7 H2O, 0.44 mM 
KH2PO4, 5.55 mM Glucose, 10.0 mM HEPES (N-[2-hydroxyethyl]piperazine-
N’-[2-ethanesulfonic acid]), 0.13 mM CaCl2 x 2 H2O, 0.05 mM MgCl2 x 6 H2O, 
0.04 mM MgSO4 x 7 H2O. For transport experiments 0.25% BSA (Sigma- 
Aldrich Chemie GmbH, Taufkirchen, Germany) was added to the HBSS buffer 
(HBSS/BSA buffer). 
Sterile BSS (balanced salt solution) contained 137.0 mM NaCl, 5.0 mM KCl, 
0.7 mM Na2HPO4 x 7 H2O, 1.2 mM MgSO4 x 7 H2O, 5.5 mM Glucose, 
10.0 mM HEPES, 0.18 mM CaCl2, 100 units/ml penicillin and 100 µg/ml 
streptomycin. All reagents were of cell culture grade. The pH was adjusted to 
7.4 with 1 M NaOH. 
2.2.2 Cells and cell culture conditions 
Calu-3 cells (HTB- 55, ATCC, Manassas, VA, USA) were cultivated in 
Minimum Essential Medium (MEM) with Earl’s Salts and L- glutamine (PAA 
Laboratories GmbH, Pasching, Austria) supplemented with 10% FCS, 1% 
MEM non- essential amino acid (NEAA) solution and 1 mM sodium pyruvate 
(all from Sigma- Aldrich). 
16HBE14o- cells were a gift from Dr. Dieter Gruenert (Department of 
Medicine, University of Vermont, Burlington, VT, USA). They were grown in 
MEM with Earl’s Salts and L- glutamine (PAA Laboratories GmbH) 
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supplemented with 10% FCS, 1% NEAA solution and 3 mM glucose (Sigma- 
Aldrich). 
Caco-2 cells (C2BBe1, ATCC) were cultivated in Dulbecco’s Modified Eagle 
Medium (DMEM) with high glucose (4.5 g/ml) and L- glutamine (PAA 
Laboratories GmbH) supplemented with 10% FCS and 1% NEAA solution. 
All cell lines were kept in 5% CO2 and 90- 98% humidity at 37°C. 
For transport studies Calu-3 (passage 27 and 32), 16HBE14o- (passage 2.68) 
and Caco-2 (passage 83) cells were seeded at a density of 60,000 cells/cm2 
on Transwell® polyester (PET) filter inserts with a growth area of 1.13 cm2 and 
a pore size of 0.4 µm (Transwell® Permeable Supports, Corning Inc., NY, 
USA). 
Primary human alveolar epithelial cells (hAEpC) were isolated from non- 
tumor lung tissue of patients undergoing partial lung resection according to 
Elbert et al. [79] with slight modifications of the enzymatic digestion and cell 
purification [83]. In brief, the chopped tissue was digested using a 
combination of 150 mg trypsin type I (Sigma) and 3 mg elastase (Worthington 
Biochemical Corp., Lakewood, NJ, USA) in 30 ml BSS for 40 min. at 37°C. 
The AT II cell population was purified by a combination of differential cell 
attachment, percoll density gradient centrifugation and positive selection of 
epithelial cells with magnetic beads (human Anti- HEA (Ep-CAM) MicroBeads, 
Miltenyi Biotec, Bergisch Gladbach, Germany). Cell viability was assessed by 
trypan blue staining. 
The isolated hAEpC were seeded at a density of 600,000 cells/cm2 on 
collagen/ fibronectin coated Transwell® polyester filter inserts (Corning Inc.) 
with a growth area of 0.33 cm2. They were grown in SAGM medium (Cambrex 
BioScience Walkersville Inc., Walkersville, MD, USA) supplemented with 1% 
FCS, 100 units/ml penicillin and 100 µg/ml streptomycin (Sigma- Aldrich). 
The formation of confluent monolayers and tight junctions was verified by 
measuring the transepithelial electrical resistance (TEER) using an epithelial 
voltohmmeter (EVOM, World Precision Instruments, Berlin, Germany) with a 
STX-2 electrode. 
For transport experiments, Calu-3 cells were used 14 days post seeding, 
16HBE14o- cells and Caco-2 cells were used after 7 and 21 days, 
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respectively. hAEpC were cultivated for 8 days. TEER values were as 
reported before or higher for transport experiments [79, 84]: about 
1000 Ω x cm2 for Calu-3, 800 Ω x cm2 for 16HBE14o-, 750 Ω x cm2 for Caco-2 
and 1400 Ω x cm2 for hAEpC. 
2.2.3 Transport studies 
Prior to transport experiments cell culture media were removed and the apical 
and basolateral compartments were washed twice with HBSS/BSA buffer. 
Cells were equilibrated for 2- 2.5 hours with this buffer. 
After the equilibration period buffer was exchanged with drug solutions of the 
same buffer in either the apical or basolateral compartment. The volumes for 
the apical and basolateral side for 16HBE14o-, Calu-3 and Caco-2 were 
500 µl and 1500 µl, respectively. The volumes for hAEpC were 200 µl for the 
apical side and 800 µl for the basolateral side. 
50 µl samples from the donor compartments were drawn immediately at the 
beginning and at the end of the transport experiments. 50 µl samples from the 
acceptor compartments were drawn after 30, 60, 120, 180, 240 and 
300 minutes. An equal volume of fresh buffer was returned to the acceptor 
compartment after each sampling. The filter plates were kept under cell 
culture conditions and were slightly shaken with an orbital shaker. TEER 
values were measured after the equilibration period and at the end of 
transport experiments to verify that the barrier function of the monolayers was 
not compromised. The drug concentrations in the donor compartments were 
as follows: 16HBE14o-: 20 µg/ml of propranolol, fluorescein and BRACO19, 
respectively; Calu-3 and Caco-2: 20 µg/ml fluorescein, 100 and 200 µg/ml 
BRACO19; hAEpC: 100 and 200 µg/ml BRACO19. 
Each experiment was performed fivefold in either direction. 
2.2.4 Transport experiments with different inhibitors 
Calu-3 cells are known to express the P- glycoprotein (P-gp) efflux system 
[85] and organic cation transporter proteins (influx/ efflux of organic cations) 
[84]. Inhibition of BRACO19 transport was studied at a donor concentration of 
200 µg/ml as described in Transport studies with the following modifications. 
For the inhibition of P-gp and other multi drug resistance efflux systems we 
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added 10 µM cyclosporin A [86] to the HBSS/BSA buffer. For the inhibition of 
organic cation transporter proteins the buffer was supplemented with 5 mM 
TEAC [87]. The inhibitors were present in both compartments. Transport 
experiments were also performed at 4°C to check for other active transport 
mechanisms as well as at 37°C without inhibitors for comparison. The results 
were compared to those of the previous experiments with Calu-3 cells. 
2.2.5 Calculation of apparent permeability coefficient Papp  
The apparent permeability coefficient Papp was calculated according to :  
  
! 
Papp (cm / sec) =
J
A "Co
 Equation 2-1 
where J is the linear section of the flux (µg/sec), A the filter area (cm2) and C0 
the initial donor concentration (µg/cm3). 
2.2.6 Determination of uptake into cells and adsorption to filter 
material 
For adsorption/ uptake studies filters were washed twice with HBSS buffer 
after the transport experiments and the filter membranes with cells were cut 
out. Cells were lysed in 1 ml of a 80:20 mixture of methanol:HBSS (v/v) by 
means of ultrasonication for 30 minutes. For removal of cell fragments the 
suspensions were first kept at -80°C for 45 minutes and were then centrifuged 
for 20 minutes at 14,000 rpm and 0°C. An aliquot of the supernatant was used 
for analysis. 
2.2.7 Sample analysis 
BRACO19 and propranolol samples were analyzed by reversed phase HPLC 
using an isocratic Dionex HPLC system consisting of an ASI 100 automated 
sample injector, UVD 340U diode array detector and P680 pump with 
Chromeleon® software (version 6.60 SP1 build 1449) (Dionex, Idstein, 
Germany). 
For BRACO19 analysis a Gemini® RP- 18 column (150 x 4.6 mm/ 5 µm/ 
110 Å) (Phenomenex, Aschaffenburg, Germany) was used. The mobile phase 
was composed of 80:20 (v/v) methanol:borate buffer pH 10.0 (100 mM). At a 
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flow rate of 0.6 ml/min the retention time of BRACO19 was 8.9 ± 0.2 minutes. 
The UV- detector was set at 268 nm. 
Propranolol was analyzed with a Lichrospher® RP- 18 column (125 x 4 mm/ 
5 µm) (Merck, Darmstadt, Germany). The mobile phase was composed of 
45:33:22 (v/v/v) water:methanol:acetonitrile supplemented with 0.033% (v/v) 
triethylamine and 0.044% (v/v) phosphoric acid. The flow rate was set to 
1.2 ml/min and the retention time was 2.9 ± 0.25 minutes. Propranolol was 
detected at 215 nm. 
Injection volumes for both substances were 20 µl per sample. 
Fluorescein was analysed by fluorimetry using a Cytofluor II fluorescence 
reader with Cytofluor software version 4.2 (PerSeptive Biosystems, 
Wiesbaden- Norderstedt, Germany). 50 µl samples were diluted to 200 µl with 
1 mM NaOH in a 96- well plate. The excitation wavelength was set to 485 nm 
and the emission wavelength to 530 nm. 
All unknown samples were calculated against known standards. Standards 
were in the range of 0.02- 20 µg/ml. If necessary, samples were diluted 1:10. 
2.2.8 IAM chromatography measurements 
Immobilized artificial membrane (IAM) chromatography of BRACO19 was 
performed with a phosphatidylcholine-functionalized column (Regis 
Technologies). The mobile phase was composed of potassium buffer pH 6.8 
and acetonitrile. A Waters HPLC system W2790 and PDA detector W2996 
with Millenium32 software (Milford, Massachusetts, USA) was used for 
analysis. The classification of the drug cellular membrane interaction in terms 
of permeability was performed by the marker molecules uracil (eluting with the 
injection peak), atenolol (3.07, 50 %), ketoprofen (5.55, 92 %), 
carbamazepine (7.64, 70 %) and propranolol (11.55, 90 %). The values in 
brackets indicate the KIAM values for the compounds and the corresponding 
fraction absorbed according to the Biopharmaceutical Classification 
System [88]. 
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2.2.9 HSA binding 
HSA binding of BRACO 19 was investigated by using a human serum albumin 
functionalized column (Thermo Hypersil) according to a method developed by 
Across Barriers GmbH. The mobile phase was composed of ammonium 
acetate buffer pH 7.4 and propanol. An isocratic Waters HPLC system W2690 
and dual wavelength detector W2487 with Millenium32 software (Milford, 
Massachusetts, USA) was used for analysis. For the classification of drug 
binding the following system was established from different literature values: 
0- 40% for weak, 40- 50% for weak/ medium, 50- 85% for medium, 85- 95% 
for medium/ strong and > 95% for strong drug binding to HSA. Substances for 
calibration were acetaminophen (24% protein binding), carbamazepine 
(76 %), propranolol (90 %) and naproxen (99 %). 
2.2.10 MTT cytotoxicity assay 
Cytotoxicity of BRACO19 was tested using the methyl-thiazolyl-tetrazolium 
(MTT) assay. 16HBE14o-, Calu-3 and Caco-2 cells were grown at a density of 
60,000 cells/ cm2 on 96 well Cellstar® tissue culture plates (Greiner bio-one, 
Frickenhausen, Germany) for 6 days under cell culture conditions (see above) 
in 200 µl medium with different concentrations of BRACO19. hAEpC were 
grown under the same conditions but at a density of 30,000 cells/cm2. 
BRACO19 concentrations were in the range of 0- 50 µM. Each concentration 
was tested in quadruplicate. Cell culture medium with or without BRACO19 
was changed every other day. After 6 days the medium was exchanged for 
200 µl BRACO19- free medium and 10 µl of 5 mg/ml MTT solution in 
phosphate buffered saline (PBS) were added to each well. After 3.5 hours 
incubation the medium was removed and the cells were washed with PBS. 
200 µl of 100% isopropanol were added to each well and the plate was left for 
crystal dissolution on an orbital shaker over night. Absorption was measured 
at a wavelength of 550 nm with an UV/Vis reader (SLT Spectra, Tecan 
Deutschland GmbH, Crailsheim, Germany). Viability of cells treated with 
BRACO19 was related to cells grown in BRACO19- free medium. The IC50 
value was determined by non- linear regression using SigmaPlot® Version 9 
(SPSS Inc., Chicago, Illinois). 
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2.3 Results 
2.3.1 Solubility, cytotoxicity, protein binding and IAM 
chromatography measurements 
BRACO19 (Figure 2-1) showed good and rapid solubility of at least 2 mg/ml in 
distilled water and physiological buffer solutions in a pH range of 2.8- 7.4. For 
transport experiments we used a 2 mg/ml stock solution in HBSS/BSA buffer 
(pH 7.4) which was diluted to the desired concentration before each 
experiment in the same buffer system.  
The IC50 values found in the MTT cytotoxicity test were as follows: Calu-3 
13.6 ± 3.8 µM, 16HBE14o- 3.6 ± 1.2 µM and hAEpC 6.0 ± 0.4 µM. 
Interestingly, Caco-2 cells were not affected by BRACO19 concentrations up 
to 50 µM.  
BRACO19’s binding to human serum albumin was found to be 38% indicating 
a weak to medium protein binding referring to the reference compounds. By 
the IAM chromatography measurements BRACO19 was eluted very early 
from the column together with the injection peak. This points out a low 
potential for BRACO19 to overcome barriers like phospholipid membranes.  
2.3.2 Transport experiments 
In the first transport experiment the permeability of BRACO19 was compared 
with the high permeability marker propranolol and the low permeability marker 
fluorescein in 16HBE14o-- cells. BRACO19 transport was found to be 
asymmetrical and very low. For the apical to basolateral (AB) direction no 
transport could be detected at all. In basolateral to apical (BA) direction 
transport was about tenfold lower than for fluorescein.  
The results for Calu-3, Caco-2 and hAEpC were comparable to those found 
with 16HBE14o-- cells. Even after increasing the donor concentrations of 
BRACO19 to 100 and 200 µg/ml to facilitate detection in the receiver 
compartment no transport could be detected in AB direction for neither cell 
line. Also, in BA direction the apparent permeability coefficients were still 
lower than the permeability of fluorescein. The results of all transport 
experiments are summarized in Table 2-1. 
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Table 2-1: Apparent permeability coefficients (Papp; in cm/sec x 107) of BRACO19 in 
comparison with propranolol and fluorescein in different cell lines (16HBE14o-, Calu-3, 
Caco-2), primary human alveolar epithelial cells (hAEpC) and cell free filters. n.d. = no 
substance detectable in acceptor compartment; X = high BRACO19 concentrations led 
to a collapse of monolayer integrity. 
  16HBE14o- Calu-3 Caco-2 hAEpC filters  
without cells 
Substance initial donor 
concentration A  B B  A A  B B  A A  B B  A A  B B  A A  B B  A 
BRACO19 20 µg/ml n.d. 0.98 ± 0.23 - - - - - - 
70.08 
± 10.47 
94.50 
± 1.85 
BRACO19 100 µg/ml - - n.d. 0.25 ± 0.05 n.d. 
0.31 
± 0.03 n.d. 
0.66 
± 0.07 - - 
BRACO19 200 µg/ml - - n.d. 0.32 ± 0.05 n.d. 
0.57 
± 0.03 X X - - 
Fluorescein 20 µg/ml 4.59 
± 0.66 
9.59 
± 0.67 
1.15 
± 0.18 
1.26 
± 0.14 
9.46  
± 1.16 
8.95 
± 1.35 - - - - 
Propranolol 20 µg/ml 131.59 
± 7.37 
106.51 
± 5.97 - - - - - - - - 
 
Transport experiments with cell free filters and BRACO19 solution were 
performed under analogous conditions to look for the influence of the 
Transwell® system. The Papp values were about 100- fold higher than for filters 
with cells (data not shown), indicating that the permeation through cell free 
filters is not rate limiting. 
TEER values of all cell monolayers remained stable or even increased slightly 
during transport studies. Only in the experiment with hAEpC and 200 µg/ml 
BRACO19 donor concentrations a strong decrease in TEER to about 
200 Ω x cm2 could be found. This was accompanied by a comparably strong 
non- linear increase in BRACO19 concentrations in the respective acceptor 
compartments.  
2.3.3 Experiments with transport inhibitors and uptake/ 
adsorption studies 
The results for transport experiments with Calu-3 cells in the presence of 
different inhibitors are summarized in Table 2-2. They were comparable to 
those under normal conditions: no transport in AB direction was detected and 
the Papp values for BA transport were within the range of the former 
experiments. This indicates that efflux/ influx systems or active transport are 
not involved in the transport of BRACO19. 
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Table 2-2: Papp values (in cm/sec x 107) of BRACO19 (200 µg/ml donor concentration) in 
Calu-3 cells under normal conditions, in the presence of the P-gp inhibitor cyclosporin 
A (10 µM), the organic cation transporter protein inhibitor TEAC (5 mM) and at 4°C.   
n.d. = no substance detectable in acceptor compartment. 
  control Cyclosporin A TEAC 4°C 
Substance initial donor concentration A  B B  A A  B B  A A  B B  A A  B B  A 
BRACO19 200 µg/ml n.d. 0.27 ± 0.03 n.d. 
0.92 
± 0.10 n.d. 
0.31 
± 0.03 n.d. 
0.18 
± 0.04 
 
The asymmetry found in the transport experiments could also be observed in 
the uptake/ adsorption studies (Figure 2-2). Filters that were in direct contact 
with BRACO19 solution from the basolateral side (BA transport) contained 
more BRACO19 than those that were in contact with the solution from the 
apical side (AB transport). An exception was the transport experiment with 
hAEpC at 200 µg/ml BRACO19 donor concentration where the integrity of the 
monolayers collapsed. Here the amounts of BRACO19 in filters found for AB 
transport were similar to those of BA transport. Amounts of BRACO19 found 
in cell free filters submitted to the same conditions were comparable to those 
of BA transport. 
 
 
Figure 2-2: Amounts of BRACO19 (µg/cm2) recovered from excised filters. 
Concentrations refer to initial donor concentration of BRACO19. * = integrity of 
monolayer compromised by high BRACO19 concentration. 
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2.4 Discussion 
Our studies showed that BRACO19 has a good solubility in aqueous media in 
the concentrations that were used. The in vitro cytotoxicity of BRACO19 for 
our pulmonary epithelial cells was comparable to values found in literature for 
other cancerous cell lines derived from other organs (e.g. vulva carcinoma 
cells, breast cancer cells or uterus carcinoma cells) [67, 74, 89]. In 
comparison to “classic” anti- cancer drugs, the cytotoxicity of BRACO19 was 
within the range of cisplatin (10- 25 µM) [90, 91] but lower than for doxorubicin 
(0.4 - 2.4 µM) [92], paclitaxel (0.7- 1.8 nM) [91] or vincristine (1.9- 3.5 nM) 
[93]. However, it has to be kept in mind that the strategy of this therapeutic 
approach is the (re)induction of senescence and apoptosis by telomerase 
inhibition (i.e. a controlled cell death) and not the simple poisoning of 
malignant cells. Therefore, a high IC50 value is desired.  
Protein binding of BRACO19 to HSA was rather weak compared to reference 
drugs. The results from IAM chromatography measurements suggest that 
interaction of BRACO19 with membrane lipids is negligible because there is a 
proportional relationship between the capacity factor k’IAM and the membrane 
partitioning coefficient Km [94]. 
Our transport studies showed that BRACO19 has great problems to overcome 
biological barriers. The transport experiments with Caco-2 cells, a standard 
model for intestinal drug absorption, indicate that BRACO19 might not be 
suitable for oral administration. Burger et al. already demonstrated that tumor 
xenografts in mice did not respond to an oral treatment with BRACO19. Even 
when BRACO19 was administered intraperitoneally, only early stage tumors 
were susceptible to the medication but not late stage tumors [74].  
Since the results for the intestinal cell line Caco-2 are comparable to those of 
our bronchial cell lines 16HBE14o- and Calu-3 as well as to the primary 
alveolar cells hAEpC, we can assume that a topical application, like an 
inhalative treatment of lung cancer, will face similar problems as the oral 
route. Although a systemic availability is not needed, BRACO19 has at least 
to be able to overcome the epithelial (air/ blood) barrier to reach deeper 
regions of a lung tumor. The transport results are confirmed by 
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IAM chromatography measurements because the capacity factor k’IAM can be 
correlated with the apparent permeability coefficient Papp [95].  
Also, the concentrations used for the transport experiments are not 
representative for possible therapeutic applications because they were far 
above the IC50 values of our cells (10 µM ≈ 7 µg/ml). hAEpC were most 
sensitive to high BRACO19 concentrations in the transport experiments as 
could be seen in the strong decrease in TEER at 200 µg/ml donor 
concentration. Since the major part of the pulmonary surface belongs to the 
alveolar region, high drug concentrations would result in unwanted side 
effects. Lower concentrations, however, would result in even less drug 
absorption and inefficacy.  
The apparent asymmetry in transport can be explained with a relatively strong 
adsorption to the filter material as has been demonstrated in the experiments 
with cell free filters (Fig. 2). For transport experiments in BA direction the 
filters were rapidly saturated with BRACO19 because they were in direct 
contact with the solution. Hence, transport was not hindered. However, when 
BRACO19 was applied from the apical side, the small amounts that 
permeated across the monolayer were completely adsorbed to the filter 
material. Since the filter was not saturated at the end of the transport 
experiment no substance could be detected in the basolateral compartment. 
Differences in adsorptions (Fig. 2) were most likely due to varying amounts of 
BRACO19 adsorbed to surface mucus and proteins (for AB direction) or 
entrapped in the intercellular space. 
Our observations can be explained by BRACO19’s chemical properties. It 
contains two basic pyrrolidine rings (Fig. 1), which are very likely to be 
protonated under physiological conditions, i.e. the molecule is positively 
charged. This results in good water solubility but strongly decreases the 
interaction with hydrophobic structures like cell membranes. The small 
amounts that were transported in BA direction most probably took the 
paracellular route by passive diffusion because no active transport 
mechanisms or efflux/ influx systems like P-gp or organic cation transporter 
proteins could be identified. Also the fact that BRACO19 does not interact with 
membrane phospholipids and that higher amounts where only detectable in 
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the acceptor compartments and filters after the monolayer integrity collapsed 
argue for the paracellular way 
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2.5 Conclusion 
From our results we would suggest that BRACO19 has the typical properties 
of a class III drug substance according to the Biopharmaceutical Classification 
System (BCS): a good aqueous solubility and a very poor permeability across 
biological barriers.  
Obviously, BRACO19 is a potent substance with an interesting new mode of 
action, i.e. telomerase inhibition by G- quadruplex stabilization, but with 
challenging biopharmaceutical properties. Hence, suitable formulations for the 
efficient delivery of this compound must be developed first in order to further 
evaluate this new therapeutic concept. 
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3.1 Introduction 
During the last years the concept of telomerase inhibition for the treatment of 
cancer became an area of intensive research. Telomerase is a reverse 
transcriptase composed of the catalytic subunit human telomerase reverse 
transcriptase (hTERT) and the template RNA human telomerase RNA (hTR). 
Its substrates, the telomeres, are located at the ends of each chromosome. 
Telomeres are repetitive TTAGGG/AATCCC sequences that end in a 
3’-(TTAGGG)n single strand overhang. They form a so-called t- loop, a 
structure stabilized by associated proteins, where the single strand invades 
the double stranded region. The t- loops prevent the chromosome ends from 
end-to-end fusions and being recognized as damaged DNA. Due to the end 
replication problem during DNA duplication telomeres erode at each cell cycle 
until they approach a certain limit. Reaching this limit is an important signal for 
a cell to enter the state of cellular senescence. Cells that do not stop dividing 
will experience severe chromosomal damages leading to cell death 
(apoptosis). Since most malignant cells express telomerase they are able to 
maintain their telomeres above this limit and therefore escape these pathways 
[71, 72, 96]. Various telomerase inhibitors have been developed and 
successfully tested. They either target hTERT, hTR or the telomeres [97].  
Our studies concentrate on the topical treatment of non-small cell lung cancer 
(NSCLC) via the inhalative route. A search for suitable drug candidates led to 
the telomere targeting 3,6,9- aminoacridine derivative BRACO19 ((9- [4- (N,N- 
dimethylamino)phenylamino]- 3,6- bis (3- pyrrolodino-propionamido) acridine; 
figure 1) which acts by G-quadruplex stabilization [67, 73]. G-quadruplexes 
are planar G-quartet motifs that can form in guanine-rich DNA sequence like 
the telomeres. These structures interact with the inhibitor via π-π stacking. 
Positively charged side chains of the inhibitor interact with the negatively 
charged phosphate DNA backbone and thereby stabilize the G-quadruplex – 
inhibitor complex. Due to this mechanism telomeres are not able to form their 
native structure and hence fail to protect the chromosomes [53, 54]. 
BRACO19 has shown some promising results in studies in tumor cell cultures 
and mouse xenografts. It was reported that a treatment with BRACO19 not 
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only resulted in telomerase inhibition but also in general telomere dysfunction 
that led to atypical mitosis and consequently to apoptosis [74].  
In a previous study we characterized BRACO19 with respect to its 
biopharmaceutical properties and found it to be a typical class III drug 
substance with a good aqueous solubility but a very poor permeability across 
epithelial cell monolayers [98]. During these studies we also found that 
BRACO19 has stability problems when dissolved in aqueous media at 
physiological pH. 
In the present study we examined the influence of pH, temperature and 
dissolution media on the stability of BRACO19. We have identified potential 
decomposition products and evaluated whether they can contribute to the 
inhibitory action of this drug candidate. 
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3.2 Materials and Methods 
3.2.1 BRACO19 
BRACO19 (9- [4- (N,N- dimethylamino)phenylamino]- 3,6- bis (3- pyrrolidino-
propionamido) acridine x 3HCl; figure 1) was synthesized by ENDOTHERM 
GmbH (Saarbruecken, Germany) according to Harrison et al. [82]. Identity 
and puritiy were proven by NMR (Table 3-3) and HPLC, respectively, in 
comparison with the original compound.  
3.2.2 Buffers and cell culture medium for stability studies 
For stability studies different HBSS (Hank’s balanced salt solution) buffers 
and diluted McIlvain buffer were used. 
The basic compositions of HBSS buffers were: 137.0 mM NaCl, 5.36 mM KCl, 
4.26 mM NaHCO3, 0.18 mM Na2HPO4 x 7 H2O, 0.44 mM KH2PO4, 5.55 mM 
Glucose, 0.13 mM CaCl2 x 2 H2O, 0.05 mM MgCl2 x 6 H2O, 0.04 mM 
MgSO4 x 7 H2O. For the adjustment of the appropriate pH values in HBSS 
buffers the buffering substances were exchanged as follows: pH 7.4 and 7.0: 
10.0 mM HEPES (N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid]), 
pH 6.0: 10.0 mM MES (2-morpholinoethanesulfonic acid), pH 4.0 and 5.0: 
10.0 mM sodium acetate. pH values were adjusted with 1 M NaOH or 1 M 
HCl, respectively. 
Diluted McIlvain buffer contained 50 mM citric acid and 1.4 mM Na2HPO4. 
The pH was 2.8. Phosphate buffer was composed of 5 mM KH2PO4 and the 
pH was adjusted with NaOH to pH 7.4. 
RPMI cell culture medium was purchased from PAA Laboratories GmbH 
(Pasching, Austria) and supplemented with 10% FCS (Sigma- Aldrich Chemie 
GmbH, Taufkirchen, Germany). The pH of the cell culture medium was 7.5. 
3.2.3 HPLC- DAD analysis of BRACO19 and decomposition 
products 
BRACO19 was analyzed by reversed phase HPLC using an isocratic Dionex 
HPLC system consisting of an ASI 100 automated sample injector with 
adjustable temperature, UVD 340U diode array detector (DAD) and 
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P680 pump with Chromeleon® software (version 6.60 SP1 build 1449) 
(Dionex, Idstein, Germany). 
We used a Gemini® RP- 18 column/ 150 x 4.6 mm/ 5 µm/ 110 Å 
(Phenomenex, Aschaffenburg, Germany). The mobile phase was composed 
of 80:20 (v/v) methanol:borate buffer pH 10.0 (100 mM). At a flow rate of 
0.6 ml/min the retention time of BRACO19 was 8.9 ± 0.2 minutes. The 
wavelength of the detector was set at 268 nm. The detection and 
quantification limit of BRACO19 were 0.010 µg/ml and 0.025 µg/ml, 
respectively. Quantification was linear in the range from 0.025 to 12 µg/ml. 
3.2.4 Decomposition experiments  
All decomposition experiments were performed with the HPLC-DAD system 
described above in HPLC brown glass vials (hydrolysis grade 1; 
CS-Chromatography, Langerwehe, Germany). Decomposition experiments 
over 7 hours were performed at 37° with HBSS buffer of different pH values 
and diluted McIlvain buffer of pH 2.8. The influence of temperature on 
BRACO19 decomposition was assessed at 4°C in comparison to the 
decomposition at 37°C in HBSS buffer pH 7.4. BRACO19 was dissolved at a 
concentration of 12 µg/ml in each respective buffer. 20 µl samples were 
drawn every 45 minutes for 7 hours and analyzed by HPLC as described 
above. Each experiment was done in triplicate. 
Long-term decomposition experiments were performed for four days in HBSS 
buffer pH 7.4, phosphate buffer pH 7.4 and RPMI cell culture medium 
containing 10% FCS (pH 7.5), respectively. The concentration of BRACO19 
was 12 µg/ml and the temperature was set to 37°C. Samples were drawn 
every 2.54 hours. All experiments were performed in triplicate. 
UV spectra of degradation products were recorded with the DAD detector 
during these long-term experiments. 
The decomposition of BRACO19 in different media was described 
mathematically by assuming first order kinetics. A non-weighted curve fitting 
was performed using the software Origin (Version 7.5, OriginLab Corp., 
Northampton, MA, USA) according to the equation: 
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  Equation 3-1 
where A is the amount of BRACO19 (in %) at time point ti, A0 the amount at 
time point t = 0, k the rate constant (in h-1) and t the time (in hours). 
3.2.5 Decomposition of BRACO19 for structural analysis of 
decomposition products by LC/MS and NMR 
For the analysis of the decomposition products by LC/MS and NMR 
BRACO19 was dissolved in phosphate buffer pH 7.4 at a concentration of 
55 µg/ml. The solution was kept at room temperature for 14 days (~ 20°C). 
The longer decomposition time was necessary to obtain larger amounts of 
secondary decomposition products. Decomposition was confirmed by HPLC. 
LC/MS and NMR analyses were performed with the mixture of decomposition 
products without isolation and purification of degradation products. 
3.2.6 LC/MS analysis of decomposition products 
The Surveyor®-LC-system consisted of a pump, an autosampler, and a PDA 
detector. Mass spectrometry was performed on a TSQ® Quantum (Thermo 
Electron Corporation, Dreieich, Germany). The triple quadrupole mass 
spectrometer was equipped with an electrospray interface (ESI). The system 
was operated by the standard software FinniganTM Xcalibur®  (Thermo 
Electron Corporation). 
A RP C18 NUCLEODUR® 100-5 (125 × 3 mm) column (Macherey-Nagel 
GmbH, Duehren, Germany) was used as stationary phase. The solvent 
system consisted of 0.1% formic acid (A) and 0.1% formic acid in methanol 
(B). Injection volume was 20 µl and flow rate was set to 350 µl/min. From 0 to 
10 min the percentage of B in the mixture was increased from 20% to 100% 
and kept at 100% for 3 min. From 13 to 15 min the percentage of B was 
decreased to the initial 20 %. MS analysis was carried out at a spray voltage 
of 4200 V, a capillary temperature of 350 °C and a source CID of 10 V. The 
polarity of the mass spectrometer was positive and as scan mode a full scan 
from 100 to 800 m/z was chosen as first scan event.  
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In a second scan event, the most intense ion determined in scan event one 
was collided with argon, at a collision gas pressure of 0.9 Pa and a collision 
energy of 35 V. The resulting fragments were recorded in MS/MS mode. 
3.2.7 NMR analysis of BRACO 19 and decomposition products 
In NMR analysis the 1H NMR spectra of (a) the free base of BRACO19 and 
(b) the decomposition products were compared. For this purpose aqueous 
solutions of both were lyophilized and redissolved in CD3OD. The 1H NMR 
spectra  (500 MHz) of (a) and (b) were recorded at 298K on a Bruker DRX500 
spectrometer using the standard pulse program zg30. Chemical shifts are 
given in parts per million (ppm) on the δ scale referenced to the solvent peak 
at 3.30 ppm. 
3.2.8 TRAP Assay 
The TRAP (Telomeric Repeat Amplification Protocol) assay was performed 
according to the instructions of the TRAPEZE® Telomerase Detection Kit 
(Chemicon International, Temecula, CA, USA), a modified version of the 
TRAP assay originally developed by Kim et al. [40, 99]. 50 ng of a protein 
extract from lysed A549 lung cancer cells was used per reaction. 
Decomposition products were obtained from a sample of the solution used for 
LC/MS and NMR analysis. The absence of intact BRACO19 in the mixture of 
decomposition products was verified by the HPLC-DAD method described 
above. The concentrations of BRACO19 and of decomposition products were 
2.0, 1.0, 0.5, 0.25, and 0.1 µM. The concentrations refer to the initial 
BRACO19 concentration. 1 µM BRACO19 and decomposition products, 
respectively, were added to the control template TSR8. Cell lysis buffer was 
included as negative control. TRAP products were separated on a 12.5 % 
non- denaturating polyacrylamide gel. DNA fragments were visualized after 
SYBR® Green I staining (Molecular Probes, Eugene, OR, USA) with the Gel 
DocTM 2000 Gel Documentation System from BioRad (BioRad Laboratories 
GmbH, Munich, Germany). 
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3.3 Results 
3.3.1 Stability experiments 
The stability of BRACO19 in solution was found to be dependent on pH and 
temperature. As can be seen from Figure 3-1 A at 37°C the stability of 
BRACO19 increased gradually with decreasing pH of the HBSS buffer. It was 
least stable at pH 7.4 while at pH 2.8 (McIlvain buffer) no decomposition 
occurred. Also, when BRACO19 was dissolved in HBSS buffer pH 7.4 and 
analyzed at 4°C and 37°C the decomposition at 4°C was considerably slower 
than at 37°C (Figure 3-1 B). An exchange of the brown glass HPLC vials with 
clear glass vials or polypropylene vials did not affect the results of the stability 
assays (data not shown). 
 
Figure 3-1: (A) Stability of BRACO19 at 37°C in HBSS buffers of different pH values 
(pH 7.4 – pH 4) and McIlvain buffer (pH 2.8); (B) Stability of BRACO19 in HBSS buffer 
pH 7.4 at 4°C and 37°C. 
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In long-term experiments the type of dissolution medium exerted a less 
important influence on the stability of BRACO19 than the variation of pH or 
temperature. As can be seen from Figure 3-2 and Table 3-1 the 
decomposition was fastest in HBSS buffer pH 7.4. In standard phosphate 
buffer and RPMI cell culture medium the stability was only slightly better. The 
half-life in HBSS buffer was about 2.9 hours. In phosphate buffer and RPMI 
cell culture medium half-lives were about 4 and 4.4 hours, respectively. 
 
Table 3-1: Rate constants, half-lifes (t1/2) (± standard error) and R2s of fits for the 
decomposition of BRACO19 in HBSS buffer, phosphate buffer and RPMI cell culture 
medium at 37°C. 
Medium Rate constant (h-1) t1/2 (hours) R2 of fit 
HBSS buffer pH 7.4 0.303 ± 0.026 2.9 ± 0.17 0.986 
Phosphate buffer pH 7.4 0.174 ± 0.012 4.0 ± 0.27 0.985 
RPMI cell culture medium pH 7.5 0.157 ± 0.016 4.4 ± 0.45 0.967 
 
Total decomposition occurred within one day in all solutions at 37°C. Four 
decomposition products (termed Decomp1 – 4) were identified during these 
long-term experiments in HBSS buffer and phosphate buffer. Their retention 
times in the HPLC-DAD system are given in Table 3-2. 
 
Table 3-2: Retention times of BRACO19’s decomposition products after decomposition 
in HBSS buffer pH 7.4 (average ± standard deviation). For HPLC-DAD parameters see 
Material and Methods. 
 BRACO19 Decomp1 Decomp2 Decomp3 Decomp4 
Retention time (min) 8.20 ± 0.20 6.71 ± 0.02 5.16 ± 0.01 5.38 ± 0.02 4.44 ± 0.02 
 
The decomposition products could easily be distinguished by their UV spectra 
and were the same in HBSS buffer and phosphate buffer (Figure 3-3). In cell 
culture medium only Decomp2 could be detected under the given conditions 
(data not shown). As can be seen from Figure 3-4 Decomp1 and Decomp2 
appeared first but were also instable. Their decay curves resemble a 
Bateman-function as seen in pharmacokinetics after oral administration of a 
drug. Decomp3 and Decomp4 appeared much slower and showed a steady 
increase over time and might be the decomposition products of Decomp1 and 
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Decomp2. However, since the exact structures and concentrations of the 
decomposition products were unknown a calculation of kinetic parameters 
was not possible. 
 
 
Figure 3-2: Decomposition of BRACO19 in HBSS buffer pH 7.4 (A), phosphate buffer 
pH 7.4 (B) and RPMI cell culture medium pH 7.5 (C). Curves were fitted according to 
Equation 3-1 assuming first order kinetics. Fit results are given in Table 3-1. 
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Figure 3-3: UV/Vis spectra of BRACO19 and its decomposition products in the range 
from 200 to 600 nm. The spectra were obtained during long-term HPLC-DAD analysis 
with methanol : borate buffer pH 10 (80:20) as mobile phase. A: BRACO19, 
B: Decomp1, C: Decomp2, D: Decomp3, E: Decomp4. Spectra are corrected for spectra 
of mobile phase. 
 
Figure 3-4: Decomposition of BRACO19 at 37°C in HBSS buffer pH 7.4 over 4 days as 
determined by HPLC-DAD analysis. Decomp1 and Decomp2 are the first 
decomposition products of BRACO19 while Decomp3 and Decomp4 appear to be the 
decomposition products of Decomp1 and Decomp2. Each data point represents mean 
± standard deviation of 3 independent measurements. 
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3.3.2 LC/MS and NMR analysis 
The analysis of the decomposition mixture by LC/MS resulted in the discovery 
of a molecule with a mass (m/z) of 144.2, which corresponds to the mass of 
the [M+H]+ of 3-pyrrolidino propionic acid (structure 2 in Figure 3-5), i.e. the 
residue of the amide groups in position 3 and 6 of BRACO19. Thus, 
hydrolysis of these amides seems to be likely. However, no molecule ions 
were found that would match the corresponding reaction products (structures 
3 and 4 in Figure 3-5). Instead, molecule ions with masses of 567.6, 442.5 
and 317.3 were detected. These masses correspond to the [M+H]+ of 
structures 5, 6, and 7, respectively, indicating a deamination in 4’ position, i.e. 
an exchange of the dimethyl amino group for a hydroxyl group. In MS/MS 
scans a fragment with the mass of 84.2 was found for structures 2, 5, and 6 
but not for structure 7. This fragment matches the structure of N-methyl 
pyrrolidine and confirms the hypothesis of a hydrolysis of the amide groups. 
 
Figure 3-5: The suggested reaction scheme for the decomposition of BRACO19 
(1 = BRACO19). The most important reactions for the decomposition seem to be the 
hydrolysis of the amide groups in position 3 and 9 and the deamination of the dimethyl 
amine group in position 4’ of the phenyl ring. 
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The NMR analyses of the decomposition products confirm the findings of 
LC/MS analysis. The results of the measurements are given in Table 3-3. In 
the aromatic part of the 1H NMR spectrum signals of two compounds (i) and 
(ii) can be found in a ratio of 5 to 1. The data of the major compound (i) are 
close to those of BRACO19 but lack signals for a dimethyl amino group in the 
aliphatic part of the spectrum, indicating the presence of a hydroxyl instead of 
the dimethyl amino group. The data of (i) are in good accordance with 
structure 5.  Investigation of the NMR spectral data of the minor compound (ii) 
showed that in contrast to BRACO19 the signals of the outer rings of the 
acridine system are not identical anymore. The difference of the chemical 
shifts of both benzene subunits (δ 8.33, 7.99, 7,21 vs. 7.71, 6.69, 6.65) 
suggests that the molecule has only one 3-pyrrolidino propionic acid group. 
Correspondingly, the aliphatic part of the 1H NMR spectrum reveals only 
signals for one 3-pyrrolidino propionic acid moiety. This together with the fact 
that the dimethyl amino group is absent leads to structure 6 for compound (ii).  
The solution must also contain free 3-pyrrolidino propionic acid (structure 2), 
since the values for the integrals of the 3-pyrrolidino propionic acid groups are 
bigger than required for pure compound i and ii. 
 
Table 3-3: 1H NMR spectral data of compounds BRACO 19, (i) and (ii). Coupling 
constants are given in parentheses. s = singlet, d = douplet, brs = broad singlet, 
brd = broad douplet. Signals indicated as m were unresolved or overlapped multiplets. 
 BRACO 19 (i) (ii) 
 δH  (ppm) δH (ppm) δH (ppm) 
1 7.91 brd (J = 9) 7.99 brd (J = 9) 7.71 brd (J = 9) 
2 7.20 brd (J = 9) 7.25 brd 6.69 brd (J = 9) 
4 8.09 brs 8.39 brs 6.65 brs 
5 8.09 brs 8.39 brs 8.33 brs 
7 7.20 brd (J = 9) 7.25 brd (J = 9) 7.21 brd (J = 9) 
8 7.91 brd (J = 9) 7.99 brd (J = 9) 7.99 brd (J = 9) 
2´, 6´ 6.80 d (J = 8.5) 7.13 d (J = 8.5) 7.13 d (J = 8.5) 
3´, 5´ 6.90 d (J = 8.5) 6.89 d (J = 8.5) 6.89 d (J = 8.5) 
1´´  2.88 m (2H) 3.07 m 3.07 m 
2´´ 2.64 m (2H) 2.79 m 2.79 m 
3´´, 6´´ 2.66 m (4H) 2.84 m 2.84 m 
4´´, 5´´ 1.84 m (4H) 1.91 m 1.91 m 
NCH3 2.88 s (6H) ------------- ------------- 
 
Chapter 3 - Decomposition of BRACO19 in Physiological Media 
   
 51 
3.3.3 TRAP Assay 
Decomposed BRACO19 (1 and 2 µM) was still able to reduce the number and 
intensities of the bands representing the “telomere ladder” (Figure 3-6, 
D1 - D5). When compared to intact BRACO19 (Figure 3-6, B1 - B5) the 
decomposition products showed a reduced inhibitory effect. Inhibition of 
telomerase with BRACO19 at a concentration of 0.25 µM clearly reduced the 
band intensities of the telomerase products. At 0.5 µM the length of the 
telomere ladder was considerably shorter. For the decomposition products the 
same effects were observed at 1 and 2 µM, respectively, demonstrating their 
reduced inhibitory potential. Both, BRACO19 and the mixture of 
decomposition products, influenced the amplification of the TSR8 internal 
standard. For BRACO19 no bands could be found. The decomposition 
products reduced the band intensities slightly (Figure 3-6 T, TB and TD).  The 
bands in the control Lane (Figure 3-6 C) are most likely due to primer-dimer 
artifacts. Figure 3-6 is representative for two TRAP assays that were 
performed with BRACO19 and its decomposition products. 
 
Figure 3-6: The TRAP assay shows the effects of BRACO19 and its decomposition 
products on telomerase activity. The assay was performed with the same material that 
has been used for LC/MS and NMR analysis. 0 = positive control; B1 – B5 = BRACO19 
2, 1, 0.5, 0.25 and 0.1 µM; D1 – D5 = mixture of decomposition products 2, 1, 0.5, 0.25 
and 0.1 µM (referred to initial BRACO19 concentrations); T = TSR8 internal standard, 
TB = TSR8 internal standard with 1 µM BRACO19; TD = TSR8 internal standard with 
1 µM decomposition products; C = negative control (lysis buffer). This figure is 
representative for two TRAP assays that were performed with BRACO19 and its 
decomposition products. 
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3.4 Discussion 
Our experiments demonstrate that the stability of BRACO19 considerably 
depends on pH and temperature of standard buffers used in biological test 
systems. At physiological pH BRACO19 decomposed in simple phosphate 
buffer as well as in more complex cell culture medium. One important 
mechanism of this decomposition seems to be a hydrolysis of the amide 
bonds in position 3 and 6 of the acridine part of the molecule as has been 
shown by LC/MS and NMR analysis. The decomposition is pH dependent and 
can be approximated by first-order kinetics. The primary decomposition 
products were also unstable and decomposed further into other products. 
However, since the exact structures and concentrations of the decomposition 
products are unknown a determination of kinetic parameters was not feasible. 
Derivatives of 9-aminoacridine are described to be prone to hydrolysis in 
position 9 resulting in acridones [100]. In our studies such products could not 
be found. Instead, a deamination in 4’- position of the phenyl residue seems 
to be more likely. 
BRACO19 has been described as the prototype of a new generation of 
aminoacridine based anti-cancer drugs that act as telomerase inhibitors by 
G-quadruplex stabilization in telomeres. A modification of the acridine ring in 
position 3 and 6 with an aminoalkylamide side chain containing a basic 
heterocycle (i.e. the pyrrolidine ring in BRACO19) is essential to obtain stable 
complexes between the quadruplex structures and the drug molecule. The 
heterocycle is protonated under physiological conditions and thus positively 
charged. The side chains are directed towards the G-quadruplex grooves 
where they can interact with the negatively charged phosphate backbones of 
the DNA [82, 101, 102]. Moore et al. have shown that 9-aminoacridine 
derivatives without these side chains in position 3 and 6 form only very weak 
complexes and are not able to inhibit telomerase activity [103]. Our results 
show that the decomposition, i.e. the hydrolysis of the side chains and the 
deamination in 4’- position strongly influences the inhibitory effect of 
BRACO19. In the TRAP assay a significant reduction of telomerase activity 
only occurs at the highest concentration of decomposition products derived 
from 2 µM BRACO19 (Figure 3-6 D1). The interference with the amplification 
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of the TSR8 standard is not as pronounced as with BRACO19 as can be seen 
in figure 7 when lines T, TB and TD are compared. TSR8 is an oligonucleotide 
composed of the TS-primer + 8 telomeric repeats. In the TRAP assay it is 
normally used as a quantitation control in the absence of telomerase. In a 
previous study we were able to show that BRACO19 strongly interferes with 
the amplification of the TSR8 oligonucleotide during PCR [73]. The 
mechanism for this interference is the formation and stabilization of 
G-quadruplexes within TSR8, which prevents a proper PCR reaction [104]. 
The reduced inhibition of the amplification of TSR8 by the decomposition 
products indicates that the affinity of the decomposition products to 
G-quadruplex structures is strongly reduced. Whether the remaining inhibitory 
effect can be attributed to one of the decomposition products alone or to all of 
them will be the matter of further studies. A reasonable order for inhibitory 
potential can be established by following the degree of hydrolysis of the 
pyrrolidino-propionamido groups: structure 5 > structure 6 > structure 7 
(Figure 3-5).  
The instability of BRACO19 under physiological conditions will cause some 
problems when the agent is used in biological test systems. Concerning the 
animal studies that were performed so far [74] it would be interesting to gain 
more knowledge about the metabolism of BRACO19, i.e. if the effects that 
have been described are really due to BRACO19 or one of its decomposition 
products. 
In conclusion, G-quadruplex stabilizing substances from the class of 
alkylamidoacridines like BRACO19 appear to be promising new drug 
molecules for the treatment of cancer by telomerase inhibition and telomere 
dysregulation. 
However, the results presented in this study show that this class of 
compounds may face stability problems during the preparation of dosage 
forms, their storage and after application. This might have serious 
consequences for the therapeutic success. Any new drug candidate should be 
submitted to thorough stability investigations prior to in vitro and in vivo tests. 
We have shown previously that BRACO19 is also a problematic substance 
from the biopharmaceutical point of view [98]. Since research in this field is 
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continued and new substances based on the alkylamidoacridine structure are 
being developed [105] it can be concluded that compounds like BRACO19 will 
require either further chemical modifications or a suitable formulation and 
delivery strategy to i) improve their biopharmaceutical properties and 
ii) reduce stability problems. 
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4.1 Introduction 
The treatment of genetic disorders by the administration of exogenous 
plasmid DNA or the inhibition of gene expression by antisense 
oligonucleotides or siRNA are promising approaches for the treatment of 
severe diseases like cancer in the future. However, it is a well-recognized fact 
that the main obstacle for gene therapy or the therapeutic application of 
antisense oligonucleotides and siRNA is the lack of a safe and efficient 
delivery strategy for nucleotide-based drugs in vivo. 
Our studies focus on the treatment of non-small cell lung cancer by 
telomerase inhibition. Telomerase is a ribonucleoprotein with reverse 
transcriptase activity that plays an important role in cell immortalization and 
cancer development by maintaining chromosomal ends, the telomeres. 
Telomeres are non-coding, repetitive hexameric (TTAGGG)n sequences that 
form lasso-like structures. They are important for chromosomal protection and 
the control of cell proliferation. In normal cells telomeres shorten during each 
cell cycle due to the end-replication problem. When they reach a certain limit it 
is a signal for the cell to stop dividing and enter the state of cellular 
senescence. Further cell divisions would result in non-functional telomeres 
and severe chromosomal damages. Cells that express the enzyme 
telomerase, like most cancer cells, escape this mechanism and can divide 
indefinitely. Therefore, the reintroduction of the normal cell cycle by 
telomerase inhibition is an interesting strategy for cancer treatment [71, 72]. 
A search for suitable telomerase inhibitors resulted in an antisense 
2’-O-methyl-RNA (2OMR) [73] directed against the template region of human 
telomerase RNA (hTR) that has been reported to be a highly potent and 
sequence-selective inhibitor of human telomerase [48, 106]. Our group 
previously developed chitosan-coated poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles based on an emulsion – diffusion – solvent-evaporation method. 
These nanoparticles proved to be efficient carriers for the delivery of plasmid 
DNA into A549 lung cancer cells in vitro and lungs of mice after intranasal 
administration in vivo [107, 108]. The advantage of these nanoparticles is that 
their properties with respect to size and surface charge can easily be modified 
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in a controlled manner by varying the amounts of PLGA, chitosan and PVA 
during particle preparation [109]. However, although plasmid DNA and 
antisense oligonucleotides might be regarded to be similar from the chemical 
point of view their differences in size are likely to influence the properties of 
complexes formed with nanoparticles and hence their biological efficacy. 
Therefore, a re-evaluation of these chitosan/PLGA nanoparticles as a carrier 
system for antisense 2OMR was necessary. The aim of the present study was 
to evaluate the nanoparticles with regard to binding efficiency, complex 
stability of nanoplexes in biologically relevant media, their delivery efficacy of 
the telomerase inhibitor to lung cancer cells and the inhibition of telomerase 
activity. 
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4.2 Materials and Methods 
4.2.1 Materials 
Poly(lactic-co-glycolic acid) (PLGA) 70:30 was purchased from Polysciences 
Europe GmbH (Eppelheim, Germany), polyvinylalcohol (PVA) Mowiol® 4-88 
from Kuraray Specialities Europe GmbH (Frankfurt, Germany), ultrapure 
chitosan chloride ProtasanTM  UP CL113 with a molecular weight of 
50 - 150 kDa and a degree of deacetylation between 75 and 90% from 
NovaMatrix (FMC BioPolymer, Drammen, Norway) and ethyl acetate from 
Fluka Chemie GmbH (Buchs, Switzerland).  
Antisense oligonucleotide 2’-O-Methyl-RNA (2OMR) with a phosphorothioate 
(ps) backbone (5' -2' -O- methyl [C(ps)A(ps)GUUAGGGUU(ps)A(ps)G]-3') 
directed against human telomerase RNA (hTR), its carboxyfluoresceinamine 
labeled derivative 5'-FAM-2OMR and a mismatch sequence (5' -2' -O- methyl 
[C(ps)A(ps)GUUAGAAUU(ps)A(ps)G]-3') were obtained from Biomers.net 
GmbH (Ulm, Germany). 
4.2.2 Nanoparticle preparation 
Chitosan-coated PLGA nanoparticles were prepared by an emulsion-diffusion-
evaporation technique as described by Kumar et al. [107] and Nafee et al. 
[109]. In brief, 5 ml of PLGA dissolved in ethyl acetate (20 mg/ml) were added 
dropwise to 5 ml of an aqueous chitosan solution containing 2.5% w/v PVA 
under magnetic stirring. The emulsion was stirred at 1000 rpm for 1 hour. 
Afterwards, it was homogenized using an UltraTurrax T25 (Janke & Kunkel 
GmbH & Co-KG, Germany) at 13,500 rpm for 15 minutes. The homogenized 
emulsion was diluted to a volume of 50 ml under constant stirring with 
MilliQ-water. Remaining ethyl acetate was evaporated by continuous stirring 
over night at room temperature. The concentrations of chitosan in the 
aqueous phase were varied to obtain nanoparticles with different surface 
charges as has been shown by Nafee et al. [109]: 0 mg/ml (pure PLGA 
nanoparticles; PLGA-NP), 0.5 mg/ml (05CPNP), 1 mg/ml (1CPNP), 3 mg/ml 
(3CPNP) and 6 mg/ml (6CPNP). The abbreviations in parentheses will be 
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used throughout the document as reference to the different particle 
preparations. CPNP stands for chitosan-coated PLGA nanoparticles. 
Red fluorescently labeled chitosan/PLGA nanoparticles were prepared as 
described above but with 2 µM of the lipophilic dye DiI (1,1′-Dioctadecyl-
3,3,3′,3′-tetramethylindocarbocyanine perchlorate; from Sigma-Aldrich 
Chemie GmbH, Taufkirchen, Germany) in the organic phase. The chitosan 
concentration for this preparation in the aqueous phase was 3 mg/ml 
(DiICPNP). 
4.2.3 Purification of nanoparticles 
Chitosan/PLGA nanoparticles were purified from excess PVA by preparative 
size exclusion chromatography (SEC) using an FPLC® system from 
Pharmacia Biotech (now Amersham Biosciences; Uppsala, Sweden) 
equipped with two P-500 pumps, a LCC-501 Plus controller, a MV-7 injection 
valve, a 50 ml Superloop, a C 16/70 column with one AC 16 adaptor, an 
Uvicord SII detector with an interference filter of 206 nm and a FRAC-100 
fraction collector. Stationary phase was Sephacryl 1000-SF® from 
GE Healthcare (Munich, Germany) with a dimension of 65 cm in height and 
1.6 cm in diameter. Mobile phase was degassed MilliQ-water containing 
0.1 mM HCl. The system was operated by the FPLCdirectorTM version 1.3 
(Pharmacia Biotech). 
Nanoparticles were filtered through non-sterile a 0.2 µm cellulose acetate filter 
(Chromafil® GF/PET-20/25, Macherey-Nagel, Düren, Germany) prior to 
purification to prevent clogging of the stationary phase. Injection volumes 
were 5 – 7 ml per run. Flow rate of mobile phase was 1 ml/min under isocratic 
conditions. Purified particles were collected and concentrated by ultrafiltration 
using Vivaspin 20® (Sartorius, Göttingen, Germany) with a molecular weight 
cut-off of 300,000 Da at 1000 x g. Afterwards they were sterile filtered 
(0.2 µm, Minisart® sterile cellulose acetate filter, Sartorius). Concentrations of 
nanoparticles were determined gravimetrically after lyophilization. PVA from 
pure PLGA nanoparticle suspension was removed by five centrifugation/ 
resuspension (with MilliQ- water) cycles in Vivaspin 20® because it was not 
possible to purify the pure PLGA nanoparticles by the size exclusion method 
described above. Purified and sterile filtered particle suspensions were stored 
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at 4°C. For a more detailed description of the purification method see Chapter 
5. 
4.2.4 Characterization of nanoparticle properties 
Particle characteristics were determined directly after preparation, after 
purification, concentration and filtration and after a storage period of about two 
months at 4°C. They were characterized with respect to size, polydispersity 
index (PdI) and surface charge. Size and PdI were determined by photon 
correlation spectroscopy and surface charge by measuring the zeta potential 
in a ZetaSizer Nano ZS from Malvern Instruments Ltd (Worcestershire, UK). 
The ZetaSizer was equipped with a 4 mW He-Ne laser. Measurements were 
performed at 633 nm and a backscattering angle of 173°. Samples were 
diluted in MilliQ water. All measurements were performed in triplicate at 
25°C using the standard settings for water as dispersion medium. 
4.2.5 Formation of 2OMR-Chitosan/PLGA nanoplexes 
Complexation experiments were performed in MilliQ water, phosphate 
buffered saline (PBS) pH 7.4 and RPMI cell culture medium (without phenol 
red; PAA Laboratories GmbH, Pasching, Austria) containig 10% fetal calf 
serum (FCS; Sigma- Aldrich). For this purpose a fixed amount of 
2’-O-Methyl-RNA (2OMR) was mixed and incubated with different amounts of 
purified chitosan/PLGA nanoparticles. The concentration of oligonucleotides 
was 4 µM which corresponds to 17.72 µg/ml for non-labeled 2OMR and 
19.84 µg/ml for 5’-FAM-2OMR, respectively.  
For complex formation 100 µl of a 5-fold concentrated oligonucleotide solution 
in MilliQ water was mixed with particles at the following weight:weight ratios 
(concentrations in parentheses refer to the final concentrations of particles in 
the suspensions): 1:0 (= 100% unbound oligonucleotides), 1:1 (17.72 µg/ml 
particles), 1:5 (88.6 µg/ml particles), 1:10 (177.2 µg/ml particles), 1:25 
(443 µg/ml particles), 1:50 (886 µg/ml particles) and 1:100 (1772 µg/ml 
particles). The mixtures were vortexed thoroughly and incubated at room 
temperature for about 10 minutes. Afterwards the volume was made up to 
500 µl with MilliQ water, PBS buffer or RPMI cell culture medium (without 
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phenol red) supplemented with 10% FCS, respectively, vortexed again and 
incubated at room temperature for another 15 minutes. 
After incubation the nanoplex suspensions were centrifuged at about 
23,000 x g and 25°C for one hour. Samples from the supernatant were 
analyzed for unbound oligonucleotide. 2OMR was determined by HPLC 
analysis. 5’-FAM-2OMR in cell culture medium was quantified by fluorimetry. 
All experiments were performed in triplicate.  
4.2.6 HPLC analysis of 2’-O-Methyl RNA 
2’-O-Methyl RNA (2OMR) from complexation experiments was quantified by 
reversed phase HPLC using an gradient Dionex HPLC system consisting of 
an ASI 100 automated sample injector, UVD 170S detector and P580 gradient 
pump with Chromeleon® software (version 6.50 SP5 build 1023) (Dionex, 
Idstein, Germany). 
The column was a Gemini® RP- 18 column (150 x 4.6 mm/ 5 µm/ 110 Å) from 
Phenomenex (Aschaffenburg, Germany). Mobile phase A was composed of 
10 mM triethylammonium acetate buffer pH 7.0, mobile phase B was pure 
acetonitrile. The gradient was as follows: 0 – 0.3 min: 100% A; 0.3 – 3.3 min: 
100% A – 80% A, 20% B; 3.3 – 6.0 min: 80% A, 20% B; 6.0 – 9.0 min: 80% A, 
20% B – 100% A; 9.0 – 17.0 min: 100% A. Column temperature was 40°C 
and the UV detector was set to 260 nm. Injection volume was 50 µl per 
sample. At a flow rate of 1 ml/min the retention time of 2OMR was 
6.47 ± 0.04 minutes. Detection and quantification limits were 0.025 and 
0.050 µg/ml, respectively. Standards were in the linear range of 
0.05 - 20 µg/ml.  
4.2.7 Quantification of 5’-FAM-2’-O-Methyl RNA 
5’-FAM labeled 2OMR was quantified by fluorimetry using a Cytofluor II 
fluorescence reader with Cytofluor software version 4.2 (PerSeptive 
Biosystems, Wiesbaden- Norderstedt, Germany). 150 µl samples from the 
supernatant were transferred into a 96- well plate and directly measured. The 
excitation wavelength was set to 485/20 nm and the emission wavelength to 
530/30 nm. Standards were in the linear range of 0.5- 20 µg/ml. 
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4.2.8 Cell cultures  
A549 (CCL-185; ATCC, Manassas, VA, USA) were cultivated in RPMI with 
L-glutamine (PAA Laboratories GmbH, Pasching, Austria) supplemented with 
10% fetal calf serum. 
Calu-3 cells (HTB- 55; ATCC) were cultivated in Minimum Essential Medium 
(MEM) with Earl’s Salts and L- glutamine (PAA Laboratories GmbH) 
supplemented with 10% FCS, 1% MEM non- essential amino acid (NEAA) 
solution and 1 mM sodium pyruvate (all from Sigma- Aldrich). 
Primary human alveolar epithelial cells (hAEpC) were isolated from non-tumor 
lung tissue of patients undergoing partial lung resection according to Elbert et 
al. [79] with slight modifications of the enzymatic digestion and cell purification 
[83]. In brief, the chopped tissue was digested using a combination of 150 mg 
trypsin type I (Sigma) and 3 mg elastase (Worthington Biochemical Corp., 
Lakewood, NJ, USA) in 30 ml BSS (137.0 mM NaCl, 5.0 mM KCl, 0.7 mM 
Na2HPO4 x 7 H2O, 1.2 mM MgSO4 x 7 H2O, 5.5 mM Glucose, 10.0 mM 
HEPES, 0.18 mM CaCl2, 100 units/ml penicillin and 100 µg/ml streptomycin) 
for 40 minutes at 37°C. The alveolar type II (AT II) cell population was purified 
by a combination of differential cell attachment, percoll density gradient 
centrifugation and positive selection of epithelial cells with magnetic beads 
(human Anti- human epithelial antigen (epithelial cells adhesion molecule; 
Ep-CAM) MicroBeads, Miltenyi Biotec, Bergisch Gladbach, Germany). Cell 
viability was assessed by trypan blue staining. They were grown in small 
airway growth medium (SAGM) (Cambrex BioScience Walkersville Inc., 
Walkersville, MD, USA) supplemented with 1% FCS, 100 units/ml penicillin 
and 100 µg/ml streptomycin (Sigma- Aldrich). The use of the human material 
for isolation of primary cells was reviewed and approved by the Ethics 
Committee of the State Medical Board of Registration of the Saarland. 
All cells were kept in an incubator set to 37°C, 5% CO2 and 95% humidity. 
4.2.9 Assessment of 2OMR association with cells by flow 
cytometry 
The association of 5’-FAM-labeled 2OMR with A549 cells was studied by flow 
cytometry by measuring the green fluorescence of the oligonucleotides after 
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incubation with nanoplexes. A549 cells were seeded in 6-well plates at a 
density of 25,000 cells per well and grown for 3 days. Nanoplexes of 
5’-FAM-2OMR and different chitosan/PLGA nanoparticles were prepared at 
ratios of 1:50 (weight2OMR/weightparticles) by incubating the different particle 
suspensions with oligonucleotides at room temperature for 15 minutes. 
Afterwards the nanoplex suspensions were diluted with RPMI cell culture 
medium containing 10% FCS to the desired final concentration of 4 µM 
5’-FAM-2OMR. The cells were incubated with these suspensions for 6 hours 
in the incubator. Subsequently, the incubation medium was exchanged for 
normal cell culture medium without nanoplexes. Controls were non-treated 
cells, cells treated with 4 µM 5’-FAM-2OMR alone and cells treated with 
particle suspensions without 5’-FAM-2OMR. Analysis by flow cytometry was 
performed the next day with a FACSCalibur flow cytometer from Becton 
Dickinson (BD) Biosciences (Heidelberg, Germany) using the software 
CellQuestTM Pro Version 4.02 (BD Biosciences). For this purpose cells were 
detached by incubation with trypsin/EDTA, washed with PBS and 
resuspended in sheath fluid (BD Biosciences). Green fluorescence was 
excited at 488 nm and measured after passing a 530/30 nm band pass filter. 
The instrument was adjusted with non-treated cells. During each run 20,000 
cells were counted. The extent of cell associated 5’-FAM-2OMR was 
evaluated after gating and selection of a fluorescence threshold referred to 
non-treated cells. The experiment was performed in triplicate. 
4.2.10 Visualization of cellular uptake by confocal laser scanning 
microscopy 
Preparation of cells 
Cells were grown in 16 well LabTek chamber slides (Nunc GmbH, 
Wiesbaden, Germany; growth area: 0.4 cm2). A549 cells were seeded at a 
density of 2500 cells per well 3 days prior to the experiment. Calu-3 cells were 
seeded at a density of 20,000 cells per well 6 days prior to the experiment. 
hAEpC were seeded in collagen/ fibronectin coated wells at a density of 
10,000 cells per well 7 days prior to the experiment. All cells were kept under 
the conditions described above.  
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For uptake experiments cells were treated with nanoplexes prepared of 
5’-FAM-2OMR and 3CPNP at a w/w ratio of 1:50. Nanoplexes were prepared 
by mixing and incubating 5’-FAM-2OMR solution and 3CPNP suspension for 
15 minutes at room temperature. The nanoplex suspension was diluted to 
4 µM 5’-FAM-2OMR with RPMI cell culture medium containing 10% FCS. 
Cells were incubated with this medium for 6 hours in the incubator. Afterwards 
the incubation medium was replaced by normal cell culture medium without 
nanoplexes. If necessary, cell culture medium was exchanged every other 
day. 
Staining of cell membranes and nuclei  
Cell membranes were stained with the red fluorescent rhodamine-labeled 
ricinus communis agglutinin I (Rho-RRCA; excitation maximum 552 nm, 
emission maximum 577 nm; Vector Laboratories Peterborough, UK). Cells 
were washed once with PBS and afterwards incubated with 25 µg/ml of 
Rho-RRCA in PBS for 15 minutes in the incubator. After two washing steps 
with PBS the cells were fixed with 4% paraformaldehyde in PBS for 
10 minutes at room temperature. 
Cell nuclei were stained with TOPRO3 (excitation maximum 642 nm, emission 
maximum 661 nm; Molecular Probes, Invitrogen GmbH, Karlsruhe, Germany). 
For this purpose the cells were washed once with PBS. Afterwards they were 
fixed and permeabilized with ice-cold (-20°C) pure ethanol for 10 minutes at 
4°C. After two washing steps with PBS the cells were incubated with 1 µM 
TOPRO3 in PBS for 15 minutes at room temperature. 
After fixation and staining the cells were washed again twice with PBS and 
were subsequently mounted in the fluorophor protector FluorSafe® reagent 
(Calbiochem, San Diego, CA, USA) and studied by confocal laser scanning 
microscopy. 
Image acquisition and processing 
Confocal laser scanning microscopy was performed with a Bio-Rad 
1024 MRC system (BioRad, München, Germany) in combination with an 
inverted Zeiss Axiovert 100 microscope (Carl Zeiss MicroImaging GmbH, 
Göttingen, Germany) equipped with a krypton/ argon laser and a 40x oil 
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immersion objective (NA 1.3). Excitation wavelengths and emission filter sets 
were dependent on the staining method and are summarized in Table 4-1. 
Table 4-1: Excitation wavelengths and filters for confocal microscopy depending on 
the staining method. (BP = band pass filter; LP = long pass filter) 
staining method excitation wavelength emission filter 
two colors (dyes)   
green (5’-FAM-2OMR) 488 nm 522/35 nm BP 
red (Rho-RRCA) 568 nm 585 nm LP 
three colors   
green (5’-FAM-2OMR) 488 nm 522/35 nm BP 
red (DiI) 568 nm 605/32 nm BP 
far red (TOPRO3) 647 nm 680/32 nm BP 
 
A step motor was used for the acquisition of 3D images. Images were 
processed using the software Volocity® (Improvision, Tübingen, Germany). 
XY-images in Figure 4-5 and Figure 4-6 are presented in “extended focus” 
mode, i.e. an overlay of all images in an image stack merged into one image 
for better presentation. XZ- and YZ cross sections from the image stacks were 
used to verify the localization of the green fluorescence of 5’-FAM-2OMR with 
respect to the stained membrane. 
4.2.11 Cytotoxicity experiments and monolayer integrity 
Cytotoxicity of 3CPNP was determined by the MTT ((3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay. A549 cells were seeded on 
96-well plates at a density of 10,000 cells per well and were allowed to adhere 
overnight. The next day cells were incubated for 6 hours with 3CPNP and 
nanoplexes of 2OMR and 3CPNP in cell culture medium at particle 
concentrations of 443, 886 and 1772 µg/ml. The corresponding nanoplex 
ratios were 1:25, 1:50 and 1:100 (weight2OMR /weight3CPNP ratios; where 
1 = 17.72 µg/ml = 4 µM 2OMR final concentration). Cells treated with cell 
culture medium and cell culture medium diluted with water (at a volume 
corresponding to the highest CPNP concentration) were included for 
comparison. After incubation the medium was exchanged for normal cell 
culture medium and the cells were grown for three more days. On the third 
day 10 µl of 10 mg/ml MTT solution in PBS pH 7.4 were added to each well. 
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After an incubation time of 2 hours under cell culture conditions 90 µl lysis 
buffer (15% SDS in a 1:1 mixture of dimethylformamide and water, pH 
adjusted to 4.5 with 80% acetic acid) were added to each well. Cell lysis was 
performed at room temperature overnight on an orbital shaker. Absorbance 
was measured the next day at 560 nm. Each concentration was measured in 
quadruplicate. 
The influence of chitosan/PLGA nanoparticles on the integrity of cell 
monolayers was assessed by measuring the transepithelial electrical 
resistance (TEER) using an epithelial voltohmmeter (EVOM, World Precision 
Instruments, Berlin, Germany) with an STX-2 electrode. Calu-3 cells were 
grown on 12 mm polyester (PET) Transwell® filters (Corning Inc., NY, USA) at 
a density of 100,000 cells per filter for 3 weeks. Cells were treated with 0.5, 
1 and 2 mg/ml of purified 3CPNP in cell culture medium containing 10% FCS. 
Control cells were treated with cell culture medium only and a 1:1 mixture of 
cell culture medium with sterile MilliQ water, respectively. The mixture with 
water was used to check for the influence in changes of osmotic pressure that 
might occur upon dilution of cell culture medium. Cells were incubated for 
6 hours. Afterwards the incubation medium was replaced by normal cell 
culture medium. TEER values were measured before incubation, after 3 and 
6 hours and after 3 days of incubation. Measurements were performed in 
hexaplicate. 
4.2.12 Telomerase activity measurement (TRAP) 
Cells (1 x 106) were collected and lysed in 200 µL ice-cold CHAPS lysis buffer 
(10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM EGTA, 0.1 mM Benzamidine, 
5 mM β-mercaptoethanol, 0.5 % CHAPS (3-[(3-cholamidopropyl)dimethyl-
ammonio]-1-propanesulfonate), 10 % Glycerol) for 30 min on ice. Lysates were 
centrifuged at 12,000 g for 20 min at 4°C and the supernatants were snap-frozen 
and stored at -80°C. Telomerase activity was measured in lysates containing 
0.05µg protein using a modified protocol of the TRAPeze Telomerase Detection 
Kit. The manufacturer’s protocol was modified as follows: A 6-carboxy-
fluorescein (6-FAM) labeled TS primer 5´-AATCCGTCGAGCAGAGTT-3´ and 
CX primer 5´-CCCTTACCCTTACCCTTACCCTAA-3´ were used. An internal 
telomerase assay standard (ITAS) which represents a 150 bp fragment of the 
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rat myogenin cDNA which is amplified by TS and CX primer was added in the 
reaction mix. PCR products were separated by fluorescence capillary 
electrophoresis (ABI PRISM 310 Genetic Analyzer). Fragment sizes were 
determined using the internal size standard GeneScan-500 ROX and 
collected data were analyzed with GeneScan Analysis software.  
4.2.13 Terminal restriction fragment length determination (TRF) 
DNA was isolated from cells using the phenol/chloroform extraction method, 
digested with 10 U of Hinf I, electrophoresed and transferred to a nylon 
membrane. The nylon membrane was hybridized with a digoxigenin labeled 
5′-(TTAGGG)7 telomere-specific probe and incubated with anti-DIG-alkaline 
phosphatase. The immobilized telomere probe was visualized by a 
chemiluminescent substrate for alkaline phosphatase (CDP-star, Roche). The 
membrane was exposed to X-ray film (Hyperfilm; Amersham Biosciences) 
and analyzed using AIDA software (Raytest, Straubenhardt, Germany). 
4.2.14 Statistical analysis 
One-Way-ANOVA was used for statistical analysis using the software 
SigmaStat® version 3.01 from SPSS Inc. (Chicago, Illinois, USA). Results 
were regarded to be statistically different when P < 0.05. 
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4.3 Results 
4.3.1 Nanoparticle properties 
The physico-chemical characteristics of the different nanoparticles in terms of 
size, polydispersity and zeta potential were determined directly after the 
preparation, after purification by size exclusion chromatography and after a 
storage period of about two months at 4°C. 
As can be seen from Figure 4-1 A particle sizes were in the range of 135 nm 
(PLGA-NP) to 175 nm (6CPNP). The increase in size correlated with the 
amount of chitosan. The purification procedure and storage did not affect the 
mean particle size for all preparations. In all cases the nanoparticles showed 
monomodal distribution. However, there was an increase in polydispersity 
indices (PDIs; Figure 4-1 B) after purification and storage except for 05CPNP. 
After preparation PDIs were in the range of 0.060 (PLGA-NP) to 0.160 
(6CPNP). After purification they were in the range of 0.070 (05CPNP) to 0.240 
(6CPNP) indicating a change in the size distribution because of the 
purification procedure. This observation is most probably due to a 
deglomeration of small particle agglomerates. A comparison of the size 
distribution curves before and after purification revealed that the fraction of 
smaller particles increased slightly after purification, giving rise to a 
broadening of the size distribution curves and hence an increase in PDI (data 
not shown). PDIs decreased again during storage to values below 0.190 
(6CPNP). All zeta potentials (ZPs) were positive for preparations containing 
chitosan while those for PLGA-NP were negative (Figure 4-1 C). There was a 
good correlation between chitosan content and increase in zeta potentials 
after purification. For 05CPNP, 1CPNP and 3CPNP the ZPs remained stable 
during storage. For 6CPNP there was a drop in ZP from about 42 mV to 
30 mV and PLGA-NP showed an increase from about -19 mV to -8 mV. 
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Figure 4-1: Properties of different chitosan/PLGA nanoparticles: after preparation 
(striped bars), after purification (bars with grey circles) and after storage for two 
months at 4°C (grey bars); A = size (nm), B = polydispersity index, C = zeta potential 
(mV). Measurements were performed in triplicate. Data represents mean values ± SD. 
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4.3.2 Complexation of 2OMR 
To examine complexation efficiencies and nanoplex stabilities nanoplexes at 
different 2OMR : nanoparticle w/w ratios were preformed in water and 
subsequently diluted with either water, PBS or RPMI cell culture medium + 
10% FCS. The amounts of unbound 2OMR were determined from the 
supernatant after removal of nanoplexes by centrifugation. 
In MilliQ water the amount of unbound 2OMR decreased with increasing 
amounts of nanoparticles (Figure 4-2 A). Up to a weight2OMR/weightparticles ratio 
of 1:25 there was a good correlation between the chitosan content and the 
binding: particles prepared with higher amount of chitosan bound 2OMR 
better than particles with lower amounts of chitosan. At higher concentrations 
of nanoparticles the binding efficiency was between 80 – 100% for all 
preparations. As expected, there was no binding of oligonucleotides to 
negatively charged PLGA nanoparticles. For all preparations the pH values 
decrease gradually with increasing particle concentrations from about pH 5.3 
to pH 3.2 (see insert Figure 4-2 A). 
In PBS the stabilities of preformed nanoplexes proved to be very weak. As 
can be seen from Figure 4-2 B there was practically no binding of 2OMR after 
dilution and incubation of the nanoplexes with PBS for all preparations. pH 
values remained in the neutral range (pH 7.0 – 7.4) with increasing amounts 
of chitosan-coated particles. 
A similar result was found in RPMI cell culture medium containing 10% FCS 
(Figure 4-2 C). Only at the highest particle concentrations about 10 to 20% of 
2OMR were still bound to the particles. For all preparations pH values 
remained in the neutral range of 7.4 to 7.7. 
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Figure 4-2: Binding efficiencies and complex stabilities of nanoplexes between 2OMR 
and chitosan/PLGA nanoparticles. Nanoplexes were preformed in MilliQ water and then 
diluted with: MilliQ water (A), PBS pH 7.4 (B) and RPMI cell culture medium + 10% FCS 
(C). The figure shows the percentages of unbound 2OMR recovered from the 
supernatant after centrifugation referred to the initial amounts. w2OMR/wparticles ratios are 
given on top of the figure and indicated by vertical dashed lines. Inserts: pH profiles 
for different particle concentrations in respective suspension medium. All experiments 
were performed in triplicate. Data represents mean values ± SD. 
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4.3.3 Uptake of nanoplexes 
Cell-associated levels of FAM-labeled 2OMR after incubation with different 
nanoplex preparations were studied by flow cytometry. Confocal laser 
scanning microscopy (CLSM) was used to visualize the uptake of nanoplexes 
(w2OMR/wNP ratio 1:50) and nanoparticles into A549, Calu-3 and hAEpC. 
Flow cytometry (Figure 4-3) showed an increase in green fluorescence, i.e. 
cell-associated 5’-FAM-2OMR levels, which was dependent on the 
formulation. While the incubation of A549 cells with nanoplexes of PLGA-NP 
did not increase the green fluorescence intensities, there was a shift to higher 
values with the chitosan-modified PLGA nanoparticles. Best results were 
obtained for 3CPNP and 6CPNP with about 88% and 83%, respectively. 
(Figure 4-3). An incubation of cells with plain nanoparticles (i.e. not 
complexed with 2OMR) showed no interference with this experiment (data not 
shown). 
 
Figure 4-3: Histogram from flow cytometry with A549 cells treated with nanoplexes of 
FAM-labeld 2OMR and different particle preparations at a w2OMR/wparticles ratio of 1:50. 
The green fluorescence of cells was measured 24 hours after incubation with 
nanoplexes. The results in the table were obtained after gating and selection of a 
fluorescence threshold. 20000 cells were counted per sample. Values are presented as 
mean values ± SD (n = 3). 
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The characterization of the nanoplexes with respect to size and surface 
charge at the 1:50 ratio (Figure 4-4) demonstrated that nanoplexes prepared 
with PLGA-NP and 05CPNP were negatively charged. Their sizes were 
comparable to nanoparticles without 2OMR. 1CPNP exhibited a surface 
charge around zero mV and the increase in size indicates an agglomeration of 
the nanoplexes due to the loss of electrostatic repulsion. The sizes of 
nanoplexes with 3CPNP and 6CPNP were again comparable to the 
nanoparticles without 2OMR. Both formulations possessed positive surface 
charges > 10 mV. Since the formulation with 6CPNP did not further increase 
the cell-associated fluorescence, further experiments were performed with 
3CPNP only. 
 
 
Figure 4-4: Properties of nanoplexes at a ratio of 1:50 that were used for flow 
cytometry experiments measured in MilliQ water. Bars: size (z-average; nm); dots: zeta 
potential (mV). All measurements were performed in triplicate. Data represents mean 
values ± SD. 
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CLSM demonstrated that the increase of fluorescence intensities 24 hours 
after incubation as observed in the flow cytometry experiments is due to an 
uptake and not only an adsorption of nanoplexes to the cell surface (Figure 
4-5). As can be seen in Figure 4-5 A2 – A4 the treatment of A549 cells with 
nanoplexes of 5’-FAM-2OMR and 3CPNP resulted in a strong green 
fluorescence compared to cells incubated with 5’-FAM-2OMR alone (Figure 
4-5 A1). Interestingly, the uptake of nanoplexes into A549 cells appeared to be 
a very slow process. After 6 hours of incubation the green fluorescence was 
still colocalized with the red fluorescence of the cell membranes (Figure 4-5 
A2). An uptake into the cells was observed 24 hours post incubation as can 
be seen in Figure 4-5 A3. The green fluorescence appeared mostly 
point-shaped indicating an entrapment of the nanoplexes in intracellular 
vesicles. A comparable result was obtained 48 hours after incubation (Figure 
4-5 A4). 
The uptake of nanoplexes into A549 cells was compared to the uptake into 
Calu-3 cells and non-cancerous hAEpC. In contrast to A549 cells Calu-3 cells 
also showed an uptake of 5’-FAM-2OMR alone. The green fluorescence 
intensity and distribution was comparable to cells treated with nanoplexes. 
Also, there was no adsorption to the cell membrane. The green fluorescence 
could be observed inside the cells directly after 6 hours of incubation (Figure 
4-5 B1 and B2). Comparable to A549 cells the green fluorescence could be 
observed for at least 48 hours (Figure 4-5 B3 and B4). In case of 
non-cancerous hAEpC a colocalization of nanoplexes with the cell membrane 
was observed but optical sections of these rather thin cells (< 1 µm) at least 
suggested that the nanoplexes were not internalized. The nanoplexes showed 
a patch-like pattern and where permanently colocalized with the cell 
membranes for 48 hours (Figure 4-5 C1-C4). 
Nanoplexes prepared of DiI-stained 3CPNP and 5’-FAM-2OMR (Figure 4-6) 
allowed to demonstrate that 2OMR uptake in A549 cells occurred as a 
complex with the nanoparticles although the complex stability in cell culture 
medium was very weak (compare Figure 4-2 C). As can be seen in Figure 4-6 
the green fluorescence of the oligonucleotides and the red fluorescence of the 
nanoparticles are colocalized after incubation resulting in a yellowish/orange 
Chapter 4 - Chitosan/PLGA Nanoparticles for the Delivery of Antisense RNA 
   
 76 
color. A similar result was obtained 1 and 2 days after incubation indicating a 
slow release of FAM-2OMR from complexes. However, in comparison to the 
red fluorescence the green fluorescence seemed to decrease over time. After 
5 days red cloudy structures could be found around the cell nuclei (white 
arrows in Figure 4-6). This observation is most probably due to the 
degradation of the nanoparticles and the release of DiI into the cytoplasm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Next page: 
Figure 4-5: Confocal images of A549 (A1-A4), Calu-3 (B1-B4) and hAEpC (C1-C4) 
presented in extended focus mode. Yellow lines indicate the positions of XZ- and 
YZ-cross sections through image stacks. The location of apical and basolateral sides 
are given in A1. Bars = 50 µm. A1, B1, C1: cells after 6 hours of incubation with 4 µM of 
FAM-2OMR only; A2, B2, C2: cells after 6 hours of incubation with nanoplexes of 
FAM-2OMR and 3CPNP (w2OMR/wparticles ratio: 1:50); A3, B3, C3: cells 24 hours after 
incubation; A4, B4, C4: cells 48 hours after incubation. Green fluorescence = 
FAM-labeled 2OMR; red fluorescence: cell membranes counterstained with Rho-RRCA. 
FAM-2OMR alone is not taken up into A549 cells and hAEpC (A1 and C1) but into 
Calu-3 cells (B1). A549: after 6 hours of incubation nanoplexes of FAM-2OMR and 
3CPNP are colocalized with the cell membrane (A2) but can be found inside the cells 
after 24 and 48 hours (A3 and A4). Calu-3: nanoplexes are directly taken up after 
6 hours of incubation (B2). hAEpC: The green fluorescence is colocalized with the cell 
membrane for 48 hours (C2-C4). 
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Figure 4-5 
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Figure 4-6: The uptake of 2OMR in A549 cells is mediated via nanoplexes. The green 
fluorescence of FAM-2OMR is colocalized with the red fluorescence from DiI-stained 
3CPNP. Colocalization can be observed for at least two days by the yellowish/orange 
color in the left column (“merge”). Middle column and right column: fluorescence of 
FAM-2OMR (green) and DiI-3CPNP (red), respectively. After five days red cloudy 
structures (white arrows) indicate the degradation of nanoparticles and release of DiI 
into the cytoplasm. Purple = cell nuclei counterstained with TOPRO-3. Bars = 25 µm 
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4.3.4 Cytotoxicity and monolayer integrity 
The MTT cytotoxicity assay showed that cell survival after a treatment with 
different concentrations of 3CPNP and nanoplexes of 3CPNP and 2OMR, 
respectively, is reduced to 70%- 80% of control independent of nanoparticle 
concentration (Figure 4-7). However, a treatment of cells with a mixture of cell 
culture medium and water also led to a reduced cell survival (about 90% of 
control). 
Furthermore, the treatment with nanoparticles did not show an effect on 
monolayer integrity of Calu-3 cells. When grown on Transwell® filters Calu-3 
cells typically form tight monolayers with transepithelial electrical resistance 
(TEER) values between 1300 and 1500 Ω x cm2 [110]. TEER for cells 
incubated with nanoparticles was comparable to controls during the 
incubation period and 72 hours after treatment (data not shown). 
 
 
Figure 4-7: MTT assay with purified 3CPNP: A549 cells show a reduced survival in the 
presence of nanoparticles and nanoplexes. Cells were treated with nanoplexes of the 
w2OMR/wparticles ratios 1:25 (= 443 µg/ml nanoparticles), 1:50 (= 886 µg/ml nanoparticles) 
and 1:100 (=1772 µg/ml nanoparticles). Cells treated only with plain nanoparticles in 
the corresponding concentrations were used as controls. Each concentration was 
measured in quadruplicate. Data represents mean values ± SD. 
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4.3.5 Inhibition of telomerase activity and telomere shortening 
The treatment of A549 cells with nanoplexes of either purified (Figure 4-8 A) 
or non-purified (Figure 4-8 B) 3CPNP and 2OMR resulted in comparable 
reductions of telomerase activity for both batches. 
The strongest inhibitory effect was observed after treatment with nanoplexes 
at a w2OMR/wparticles ratio of 1:100 resulting in about 60% inhibition of 
telomerase activity. However, at this ratio the mismatch control, which 
contains two mismatches relative to the template sequence [48], also showed 
a considerable telomerase inhibition. This observation is most probably due to 
non-specific effects. Best results were obtained with non-purified particles at 
the 1:50 ratio. Here a statistically significant difference between normal 2OMR 
and the mismatch sequence has been found (P < 0.05). Telomerase activity 
was decreased by about 50% with normal 2OMR while mismatch 2OMR 
showed only a slight effect. Such a statistically significant difference between 
normal and mismatch 2OMR could not found for purified particles. The 
telomerase inhibition by nanoplexes prepared with non-purified nanoparticels 
was as efficient as using the lipid-based transfection reagents DOTAP and 
MegaFectinTM, which was described recently by our group [111].  
 
Figure 4-8: Reduction of telomerase activities in A549 cells 72 hours after incubation 
with 2OMR:3CPNP nanoplexes at different w/w ratios in comparison to a 2OMR 
mismatch control. Telomerase activities were normalized to non-treated cells. 
A: nanoplexes were formed with purified 3CPNP nanoparticles; B: nanoplexes were 
formed with non-purified 3CPNP nanoparticels. Data represent mean values ± SD of at 
least 3 independent experiments. * = statistically significant difference between normal 
2OMR and mismatch control (P < 0.05, One-Way ANOVA). 
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Reduction of telomere length was examined after repetitive treatments (twice 
weekly) of A549 cells over 35 days in comparison with the lipid-based 
transfection reagents DOTAP and MegaFectinTM. As can be seen in Figure 
4-9, 3CPNP were as effective as the two commercial transfection reagents. 
Reduction in telomere length was significant for all three preparations 
compared to control (P < 0.05; One-Way-ANOVA) but there was no significant 
difference between the transfection reagents. 
 
Figure 4-9: Telomere length in A549 cells after repeated treatment with 2OMR:3CPNP 
nanoplexes over 35 days in comparison to cells treated with the commercially 
available transfection reagents DOTAP and MegaFectinTM. 3CPNP are as efficient as 
DOTAP and MegaFectinTM. * = all treated cells were statistically significant different 
from control (One-way-ANOVA; P < 0.05). There was no statistical significant difference 
between the lipid-based transfection reagents and 3CPNP. 
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4.4 Discussion 
Our results show that changing the amounts of chitosan in the preparation 
procedure can easily vary particle properties. These variations significantly 
influence their efficiency for the delivery of antisense 2OMR to lung cancer 
cells. 
The particles proved to be stable after purification and storage over two 
months and they showed a high binding of 2OMR and complex stability in 
water. However, dilution in buffered media strongly reduced complex 
formation. In our previous study, suspensions of CPNP either as particles 
alone or in complex with 2OMR proved to be stable in NaCl solution, PBS 
pH 7.4 and HBSS buffer pH 7.4 with regard to their colloidal properties. 
However, they showed a strong reduction in their surface charge when diluted 
in buffered media, which is due to the neutralization of the protonated primary 
amine groups of chitosan [109]. This charge neutralization results in a 
reduced ability to bind the negatively charged 2OMR as could be 
demonstrated by our binding/complexation experiments. Chitosan is a weak 
base. The type that was used for these experiments has a pKa value of about 
6.5 [112]. Complexes diluted in pure MilliQ water were stable because pH 
values were below this pKa resulting in protonation of most of the amino 
groups. In contrast, due to the neutralization of the positive charges, complex 
stability was strongly reduced and dissociation occurred when the preformed 
complexes were diluted in buffered media like PBS and cell culture medium 
with pH values ≥ 7.  
From these results one could expect that nanoplexes in cell culture medium 
are unstable and do not improve the uptake of 2OMR into cells. But this was 
not the case. As we could demonstrate in the following experiments with A549 
cells, uptake was significantly increased for nanoplexes prepared with 3CPNP 
and 6CPNP and telomerase was activity successfully inhibited (Figures 4-3, 
4-5, 4-6, 4-8 and 4-9). 
From the nanoplex characterizations it could be argued that the uptake 
correlated with the particle surface charge (Figure 4-4) as described by 
Lorenz et al. [113]. However, the characterization was performed in water 
while the uptake experiments were performed in cell culture medium 
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containing 10% fetal calf serum. Beside the neutralization of the surface 
charge in cell culture medium it is known that serum proteins adsorb to 
cationic nanoparticles [114, 115], which significantly influences the surface 
charge. The fact that there was no difference in uptake improvement between 
nanoplexes prepared with 3CPNP and 6CPNP indicates that the uptake 
cannot only be attributed to the surface charge but also must be related to the 
chitosan density on the particle surface. That the uptake of FAM-2OMR into 
A549 is really mediated via nanoplexes could clearly be demonstrated by 
confocal microscopy (Figure 4-5 and Figure 4-6), which shows that that there 
is no complete dissociation of complexes in cell culture medium and that the 
nanoplexes are still able to interact with the cell surface. Whether these non-
dissociated complexes corresponds to the about 15% of bound 2OMR (Figure 
4-2 C; 1:50 ratio 3CPNP) will be the subject of future studies. Fang et al. have 
shown with liposomes composed of DPPC that even at pH 7.4 an adhesion 
between chitosan and the phospholipid membrane occurs [116]. Löhbach et 
al. demonstrated that the adhesion of chitosan-coated carboxypolystyrene 
nanoparticles dispersed in PBS to endothelial cells is higher in the presence 
of FCS than without proteins [117]. Therefore, besides remaining ionic forces 
other factors like hydrogen bonds or even the combination of chitosan and 
proteins on the particle surfaces might play an important role in the nanoplex 
– cell surface interaction. 
Huang et al. reported that the uptake of FITC-labeled chitosan nanoparticles 
into A549 cells is a saturable process dependent on adsorption of particles to 
the cell membrane and subsequent clathrin-mediated endocytosis [118, 119]. 
This mechanism corresponded well to the observations in our experiments. 
The uptake of FAM-2OMR alone was very poor but the adsorption of 
nanoplexes to the cell surface significantly enhanced its internalization. The 
results from flow cytometry suggest that a certain chitosan density on the 
particle surface is required to achieve optimal adsorption. This level was 
reached in 3CPNP because 6CPNP with their higher chitosan content did not 
further increase the nanoplex uptake (Figure 4-4). The differences in chitosan 
content were shown by zeta potential measurements in this (Figure 4-1 and 
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Figure 4-2 B) and our previous study [109] where 6CPNP exhibit a higher zeta 
potential than 3CPNP.  
However, nanoplexes also adsorbed on hAEpCs, but no clear internalization 
was observed over two days. HAEpC are primary isolated human alveolar 
type (AT) II cells that acquire characteristics of AT I cells after a certain time 
under the given cell culture conditions [80]. Since AT I cells are reported to be 
deficient in clathrin-mediated endocytosis [120] this might explain the lack of 
nanoplex internalization by these cells. In contrast, Calu-3 expressing both 
clathrin and caveolin [121] showed even an uptake of FAM-2OMR alone. 
However, a closer investigation of the exact uptake mechanism was not done. 
The data from the MTT toxicity test demonstrates that the nanoparticles have 
only a slight cytotoxicity as they reduce the A549 cell growth about 20 - 30% 
(Figure 4-7). The nanoparticles did not influence the integrity of Calu-3 
monolayers, and hence their barrier function, since TEER values did not differ 
from controls. Grenha et al. reported a comparable result for chitosan 
nanoparticles in respirable powder formulations [122]. 
Furthermore, we were able to show that a treatment of A549 cells with these 
nanoplexes results in an inhibition of telomerase activity and telomere 
shortening. The comparison of our chitosan/PLGA nanoparticles with 
established transfection reagents was encouraging for further studies since 
the results were comparable to DOTAP or MegaFectinTM. However, the 
purification of CPNP does not seem to be necessary with regard to their 
biological effect because telomerase inhibition was not significantly different 
for either purified or non-purified particles. Regarding the specificity of 2OMR 
in comparison with the mismatch sequence, nanoplexes prepared with 
non-purified particles appeared to be even more effective than those prepared 
with purified particles. For this study purification was done to assure that the 
observed effects in binding and uptake experiments can only be attributed to 
the nanoparticles and not to remaining polymers in the suspensions. Since 
the presence of these polymers does not seem to influence the biological 
activity future studies concerning the long-term efficacy of nanoplexes will be 
performed with non-purified particles. 
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4.5 Conclusion 
Nanoplexes formed between cationic chitosan-coated PLGA nanoparticels 
and antisense 2’-O-methyl-RNA were efficiently taken up by human alveolar 
(A549) and bronchial (Calu-3) epithelial cancer cell lines, while cellular uptake 
was not obvious for non-cancerous human alveolar epithelial cells in primary 
culture. In thus transfected cells, a significant inhibition of telomerase activity 
and shortening of telomeres could be observed. Transfection proved to be 
dependent on the chitosan content of the nanoplexes, allowing to optimize the 
formulation for such application. The resulting nanoplexes were well tolerated 
by the cells and appeared to be equally efficient as some commercially 
available lipid-based transfection reagents. 
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Chapter 5  
Purification of chitosan/PLGA nanoparticels by size 
exclusion chromatography 
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5.1 Introduction 
The development of a suitable purification method for chitosan/PLGA 
nanoparticles was necessary to verify that the results described in Chapter 4 
could only be attributed to the particles and not to remaining free polymers in 
the suspensions. However, the purification method that was available at that 
time was based on repeated ultrafiltration-resuspension steps of nanoparticle 
suspension using the Centrisart® system from Sartorius (Figure 5-1). This 
method required centrifugation after each resuspension, which increased the 
risk for particle agglomeration. Another point was that only small volumes of 
2 ml maximum could be purified in one tube, which proved to be very time 
consuming and laborious for the purification of larger volumes. 
 
Figure 5-1: Principle of the nanoparticle purification with Centrisart® ultrafiltration 
tubes. The choice of the membrane pore size allowed the separation of free polymers 
from nanoparticles by ultrafiltration during the centrifugation step. Suspensions were 
submitted to several ultrafiltration-resuspension steps for complete removal of free 
polymers. 
Since the experiments described in Chapter 4 and long-term cell culture 
experiments required higher amounts of purified nanoparticles, another 
purification strategy was needed. We developed a method based on size 
exclusion chromatography that allowed the semi-automatic processing of 
volumes up to 50 ml, i.e. the volume of one particle preparation. 
This chapter describes the development of this purification method including 
factors that are important for a successful separation of nanoparticles from 
free polmers. 
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5.2 Materials and Methods 
5.2.1 The size exclusion chromatography system 
Size exclusion chromatography (SEC) was done using a FPLC® system from 
Pharmacia Biotech (now Amersham Biosciences; Uppsala, Sweden) 
equipped with two P-500 pumps, a LCC-501 Plus controller, a MV-7 injection 
valve, a 50 ml Superloop, a C 16/70 column with one AC 16 adaptor, an 
Uvicord SII detector with an interference filter of 206 nm and a FRAC-100 
fraction collector.  Stationary phase was Sephacryl S-1000 SF® from 
GE Healthcare (Munich, Germany) with a dimension of 65 cm in height and 
1.6 cm in diameter. The system was operated by the FPLCdirectorTM software 
version 1.3 (Pharmacia Biotech). Flow rate of mobile phase was 1 ml/min 
under isocratic conditions.  
5.2.2 Selection of mobile phase 
Three different mobile phases were tested: pure MilliQ water, 0.9% sodium 
chloride (NaCl) solution and 0.1 mM hydrochloric acid (HCl), which was 
prepared by dilution of 1 M HCl in MilliQ water. 
5.2.3 Particle suspensions 
Different chitoan/PLGA nanoparticles were prepared as described in Chapter 
4 under 4.2.2. Most parts of the method development described here were 
performed with chitosan/PLGA nanoparticles prepared with 3 mg/ml chitosan 
(3CPNP). All particle suspensions were filtered through a 0.2 µm cellulose 
acetate filter (Chromafil® GF/PET-20/25, Macherey-Nagel, Dueren, Germany) 
prior to injection. 
5.2.4 Evaluation of the separation of particles from polymers 
To demonstrate the different retention times of particles, chitosan and PVA, 
1.5 ml of each sample were injected into the SEC system. Particle suspension 
was 3CPNP. The concentrations for chitosan and PVA solutions were 
3 mg/ml and 25 mg/ml, respectively. Mobile phases were either MilliQ water 
or 0.1 mM HCl. 
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5.2.5 Quantification of chitosan and PVA in fractions after 
purification 
For the evaluation of the purification method 5 ml of a filtered chitosan/PLGA 
nanoparticle suspension was injected into the size exclusion chromatography 
system. Mobile phases were MilliQ water and 0.1 mM HCl. The flow rate was 
1 ml/min. 10 ml fractions of the eluate were collected continually over 
150 minutes. Afterwards, each fraction was submitted to ultrafiltration in 
Vivaspins 20® at 1000 x g.  8 ml of filtrate from each fraction were lyophilized 
and the dried polymers were redissolved in 4 ml MilliQ water. For comparison 
5 ml of non-purified particle suspension was diluted to 10 ml with MilliQ water 
and also submitted to ultrafiltration. 
Chitosan was quantified by mixing 0.25 ml of polymer solution with 0.25 ml 
4 M Na-acetate buffer pH 5.5 and 0.5 ml of an acetic ninhydrin reagent 
(2 g ninhydrin, 0.08 g SnCl2 x 2 H2O, 50 ml 2- methoxy ethanol, 25 ml 
4 M Na-acetate buffer pH 5.5, 25 ml water) [123]. The mixture was incubated 
at 100°C for 20 minutes on a boiling water bath. After cooling down to room 
temperature 200 µl samples were transferred to a 96 well plate and 
absorptions were measured at 550 nm with an UV/Vis reader (SLT Spectra, 
Tecan Deutschland GmbH, Crailsheim, Germany). Standards were in the 
range from 0.01 – 0.4 mg/ml chitosan. 
The concentrations of PVA were determined by mixing 100 µl of sample with 
480 µl water, 300 µl 3.8% (w/v) boric acid solution and 120 µl 0.05 M I2/KI 
solution. The mixtures were incubated in a closed container over night at 
room temperature. Absorptions were measured at 650 nm using a Lambda 25 
UV/Vis spectrophotometer from PerkinElmer (Wiesbaden, Germany). 
Standards were in the range of 0.025 – 0.25 mg/ml. If necessary, samples 
were diluted to fit the range of calibration. Every sample was measured in 
triplicate. 
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5.3 Results and Discussion 
5.3.1 Selection of the mobile phase 
Good results for the SEC of chitosan/PLGA nanoparticles were obtained with 
water and 0.1 mM HCl as mobile phase (Figure 5-2). Sharp and symmetric 
peaks appeared after about 50 minutes, which approximately corresponds to 
the dead volume of the stationary phase. The peak with water as mobile 
phase was wider than for 0.1 mM HCl. The isotonic sodium chloride solution 
proved to be unsuitable for SEC of chitosan/PLGA nanoparticles. At 
50 minutes no peak appeared. Only after about 90 minutes a low and 
asymmetric peak was found. Initially the sodium chloride solution was favored 
as mobile phase because it was intended to compensate for changes in 
osmotic pressure in uptake experiments after mixing cell culture medium with 
nanoplexes. 
 
 
Figure 5-2: Comparison of SEC chromatograms with different mobile phases: pure 
MilliQ water (black), 0.1 mM HCl (blue) and 0.9% NaCl solution (red). Particles were 
3CPNP.  
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Comparing the retention times for solutions of PVA and chitosan with water 
and 0.1 mM HCl there was no difference for the two mobile phases (Figure 
5-3 A and B). The PVA peak was well separated from the particle peak with a 
maximum at about 120 minutes. Chitosan showed a broad flat peak between 
55 and 110 minutes and partly co-eluted with particles.  
 
 
Figure 5-3: Chromatograms of particles and polymer solutions with MilliQ water (A) 
and 0.1 mM HCl (B) as mobile phase. PVA is well separated from the particle peaks 
while chitosan partly coelutes with particles. Retention times are comparable for both 
mobile phases. 
 
From the data shown so far there seems to be no great difference between 
water and 0.1 mM HCl as a suitable mobile phase. However, the reason why 
0.1 mM HCl was finally chosen for the purification of nanoparticle suspensions 
(see previous chapter) was the influence of the mobile phase on the 
purification efficiency of the low-chitosan preparation 05CPNP. Figure 5-4 A 
and B show the chromatograms from purifications of 7 ml 05CPNP 
suspensions with water and 0.1 mM HCl, respectively, as mobile phases. It 
can clearly be seen that the performance of water was very poor. The particle 
peak that was observed for 3CPNP between 40 and 60 minutes retention time 
is almost non-existent. In contrast, when 0.1 mM HCl was used a sharp peak 
was found. 
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Figure 5-4: Chromatograms of 05CPNP eluted with MilliQ water (A) and 0.1 mM HCl (B). 
When MilliQ water was used as mobile phase only a very small particle peak was 
visible. 
 
Interestingly, neither of the two mobile phases could be used for the 
purification of plain negatively charged PLGA nanoparticles. An experiment 
with a small column filled with Sephacryl 1000-SF (ca. 16 cm length x 1 cm 
diameter), which was used for quick evaluations of new experimental 
parameters, showed that no peak occurred for PLGA nanoparticles under 
both conditions, while 05CPNP could be eluted satisfactorily with 0.1 mM HCl 
(Figure 5-6). 
These results strongly suggest that particle charge strongly influences elution 
and retention. Negatively charged PLGA nanoparticles seem to interact with 
the stationary phase and their strong retention might therefore not only be due 
to the principle of size exclusion while the positive charge of chitosan coated 
particles seems to prevent this interaction. Sephacryl S-1000 SF is a 
hydrophilic matrix composed of allyl dextran cross-linked with N,N’-methylene 
bisacrylamide (Figure 5-5). The hydroxyl groups of the dextran can form 
hydrogen bonds with the negatively charged carboxyl groups of the PLGA 
polymer. Since no elution of PLGA nanoparticles occurred under both neutral 
(water) and acidic (0.1 mM HCl) conditions, where most of the negative 
charges should be neutralized, a positive surface charge seems to be 
necessary for an early elution. As has been demonstrated with 05CPNP an 
acidification of the mobile phase results in a much better elution of particles. 
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Figure 5-5: Structure of Sephacryl S-1000 SF (according to the manufaturer). 
 
 
Figure 5-6: Comparison of chromatograms of PLGA nanoparticles and 05CPNP 
obtained with a short column filled with Sephacryl 1000-SF (16 cm length x 1 cm 
diamter). A: no particle peaks were obtained when MilliQ water was used as mobile 
phase; B: the use of 0.1 mM HCl as mobile phase resulted in a sharp peak for 05CPNP 
but not for PLGA nanoparticles. 
 
5.3.2 Quantification of chitosan and PVA in different fractions 
The quantification of chitosan and PVA in fractions that were continuously 
collected during the purification procedure of 3CPNP with either water or 
0.1 mM HCl as mobile phase showed that chitosan must be almost 
quantitatively associated with the particles (Figure 5-7 A and B). No fraction 
from either mobile phase contained amounts of chitosan that were 
significantly different from a basal level that was measured for all fractions. 
Messai et al. have shown that chitosan efficiently adsorbs to the particle 
surface of pre-formed PLGA nanoparticles [124] and that it is also partly 
incorporated into particles prepared by the emulsification-diffusion-solvent 
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evaporation method employed here [125]. We were able to demonstrate in a 
previous study by zeta potential measurements that the surface of 3CPNP is 
not saturated with chitosan [109]. Hence, it is very likely that the larger fraction 
of chitosan is associated with the particles and that the amount of potentially 
unbound chitosan is below the detection limit of the assay that was used for 
these experiments. 
In contrast, high amounts of PVA were found in fractions that were collected 
between retention times of 90 to 130 minutes (Figure 5-7). This result is in 
good agreement with the retention times found for PVA injected alone into the 
SEC system and detected by UV absorbance (Figure 5-3). 
 
Figure 5-7: Quantification of chitosan and PVA from a 3CPNP particle suspension in 
fractions that were continually collected during the SEC run. A: water as mobile phase; 
B: 0.1 mM HCl as mobile phase. Chitosan (red dots) was below the quantification limit 
in all fractions. The increase in PVA in fractions 9 - 13 (= 90 – 130 minutes retention 
time) corresponded well to the peaks at 110 minutes and the chromatograms of PVA in 
Figure 5-3. 
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Calculating the total amount of PVA from all fractions showed that the 
purification with 0.1 mM HCl as mobile phase was the most efficient with 
about 7.5 mg compared to about 5.5 mg when water was used. Interestingly, 
the amount of PVA obtained from non-purified 3CPNP after a simple 
ultrafiltration was below 2 mg. Comparing these results with the expected 
amount of 12.5 mg showed that there must also be a high degree of 
association/ integration of PVA with/ into nanoparticles. The fact that the 
amounts of recovered PVA from purified particles are higher than for 
non-purified strongly indicates that PVA adsorbs to the surface and cannot be 
removed by a simple centrifugation step. During the purification procedure this 
adsorbed PVA is then washed off the surface because of the steady flow of 
mobile phase. The differences in PVA recovery with water and 0.1 mM HCl, 
respectively, as mobile phase are most probably due to the change in degree 
of protonation and conformation of surface polymers. 
 
 
Figure 5-8: Comparison of PVA recovered from purified particles (with water and 
0.1 mM HCl as mobile phase, respectively), non-purified particles after direct 
ultrafiltration and the amount expected in 5 ml particle suspension. 
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5.3.3 Purification of different nanoparticle preparations 
The purification method was employed for all chitosan/PLGA nanoparticle 
preparations that were used for the experiments described in Chapter 4. As 
can be seen in Figure 5-9 the particle peaks broadened with increasing 
chitosan concentrations, which is most probably due to a more heterogeneous 
size distribution at higher chitosan contents (compare PDIs in Figure 4-1). 
Also, 3CPNP and 6CPNP showed a stronger tailing than 05CPNP and 
1CPNP. Whether this tailing is due to subfractions of nanoparticles or 
unbound polymers, especially chitosan, could not be clarified during these 
studies. Regarding the results from the quantification experiments for free 
polymers (see above) the presence of unbound chitosan appears unlikely. 
Also, particle collection during the purifications was automatically initiated 
when peaks exceeded an absorbance value higher than 1.5 and stopped 
when absorbance dropped below this threshold again. So even if the tailing 
can be attributed to free chitosan, the amounts of the polymer within the 
particle fraction of 3CPNP and 6CPNP should be negligible concerning their 
influence on the results described in Chapter 4. 
 
 
Figure 5-9: Comparison of chromatograms from different particle preparations after 
purification with 0.1 mM HCl as mobile phase. Peaks broaden with increasing chitosan 
content in particle suspensions. 05CPNP, 1CPNP, 3CPNP and 6CPNP = chitosan/PLGA 
nanoparticles prepared with 0.5, 1, 3 and 6 mg/ml chitosan, respectively. 
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5.3.4 Repeated injection of particle suspensions 
Figure 5-10 shows the chromatogram from three successive injections of 
3CPNP during a purification run. It can clearly be seen that the peaks appear 
in a reproducible way. This shows that an additional washing or 
re-equilibration of the column is not necessary after a purification step. 
 
 
Figure 5-10: Successive injections for the purification of a larger volume of 3CPNP 
suspension. The peaks appear in a reproducible way. 
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5.4 Conclusion 
We were able to demonstrate that preparative size exclusion chromatography 
can be used as an efficient method for the purification of chitosan/PLGA 
nanoparticles from excess PVA in particle suspensions. The advantage of this 
method is that it can handle larger volumes up to 50 ml in a semi-automated 
purification procedure. Interventions of the operator are limited to the filtration 
of particle suspensions prior to and their concentration after purification. 
However, as could be demonstrated with pure PLGA nanoparticles, this 
method is limited to the purification of cationic chitosan-coated PLGA 
nanoparticels.  
 
Chapter 6 - Hyaluronic Acid-Modified Liposomes for Targeted siRNA Delivery 
   
 101 
Chapter 6  
Hyaluronic Acid- Modified Liposomes for the 
Targeted Delivery of siRNA to CD44 Expressing 
Lung Cancer Cells 
 
 
 
 
 
 
 
 
 
 
The data presented in this chapter has been accepted for publication as a 
research article in the journal Oligonuceotides: 
 
Taetz, S., Bochot, A., Surace, C., Arpicco, S., Schaefer, U.F., Marsaud, V., 
Kerdine-Roemer, S., Lehr, C.-M., Fattal, E. 
Hyaluronic acid- modified DOTAP/DOPE liposomes for the targeted delivery 
of anti-telomerase siRNA to CD44 expressing lung cancer cells. (2009) 
Oligonucleotides, accepted 
 
Journal ISSN: 1545-4576 
 
Journal Online ISSN: 1557-8526 
 
Weblink: http://www.liebertpub.com/products/product.aspx?pid=121 
 
 
  102 
Chapter 6 - Hyaluronic Acid-Modified Liposomes for Targeted siRNA Delivery 
   
 103 
6.1 Introduction 
Since its discovery, the mechanism of RNA interference via small interfering 
RNA (siRNA) developed rapidly into a powerful tool in molecular biology for 
studying the downregulation of gene expression. Due to their high efficiency 
and selectivity siRNA became rapidly interesting for medical applications like 
the treatment of severe diseases such as cancer. However, siRNA faces the 
same obstacles for a successful application as other nucleotide-based 
therapeutics like plasmid DNA or antisense oligonucleotides, i.e. a poor 
uptake and stability in serum and the lack of selectivity for the target tissue 
[126-128]. Therefore, different carrier systems based on cationic liposomes or 
nanoparticles coupled with tumor-recognizing ligands (e.g. transferin-coupled 
DOTAP/cholesterol liposomes [129], PEGylated polyethyleneimine 
nanoparticles conjugated with an RGD peptide [130] or a PEGylated 
liposome-polycation-DNA complex modified with anisamide [131]) were 
developed .  
Our study concentrated on cationic hyaluronic acid (HA)-modified 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine (DOPE) / 1,2-dioleoyl-3-trimethyl-
ammonium-propane (DOTAP) liposomes as carriers for the targeted delivery 
of a siRNA directed against the enzyme telomerase to lung cancer cells that 
over-express the HA binding receptor CD44. The discovery that many cancer 
types over-express this receptor led to the development of HA-drug 
conjugates [132, 133] and HA-modified drug carrier systems [133-139] that 
were able to target these cancer cells very specifically in vitro and in vivo. HA 
is an endogenous polymer of repeating disaccharide units of D-glucuronic 
acid and D-N-acetylglucosamine with a wide range of molecular weights. It is 
widely distributed in the mammalian body were it fulfills important mechanical 
or structural functions [140]. However, by interaction with its principal cell 
surface receptor CD44, a transmembrane glycoprotein that exists in different 
isoforms, it also plays an important role on cell – cell / cell – matrix interaction, 
cell adhesion and migration and signal transduction from the extracellular to 
the intracellular compartment [141-143]. 
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Among the carrier systems mentioned above HA-modified liposomes were 
reported to be very efficient in the delivery of anti-cancer drugs like 
doxorubicin or mitomycin C [134, 138, 139]. In mouse tumor models these 
liposomes showed a much higher efficacy compared to non-modified 
liposomes and also a longer systemic circulation time, which was attributed to 
a “hydrophilic coat effect” of the hyaluronic acid. In terms of cytotoxicity, 
CD44-expressing cells were much more sensitive to the cytotoxic drugs 
encapsulated in HA-modified liposomes while toxicity for CD44 deficient cells 
was unchanged. 
The target of the siRNA used in this study was a mRNA coding for the 
catalytic subunit of human telomerase hTERT (human telomerase reverse 
transcriptase). Telomerase plays an important role in cell immortalization and 
hence cancer development. Many types of cancer over-express this enzyme, 
which is inactive in normal somatic cells. Therefore, telomerase is believed to 
be a suitable target for the specific treatment of cancers that overexpress this 
enzyme [97]. 
The aim of our study was to prepare and characterize cationic HA-modified 
DOTAP/DOPE liposomes using a conjugate of HA and DOPE that has been 
successfully employed by Surace et al. [144] for the targeted delivery of 
plasmid DNA to CD44 expressing breast cancer cell lines. We investigated 
the influence of the modification with regard to the colloidal properties of the 
liposomes and lipoplexes, siRNA binding and protection, cytotoxicity, uptake 
into CD44 expressing and non-expressing cancer cells and the efficiency in 
telomerase inhibition in comparison with non-modified liposomes and the 
commercially available transfection reagent Lipofectamine 2000. 
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6.2 Materials and Methods 
6.2.1 Materials 
1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP) chloride salt was 
obtained from Avanti Polar Lipids (Alabaster, AL, USA), 1,2-Dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) and 1-ethyl-3-[3-
dimethyl)amiopropyl]carbodiimide hydrochloride (EDAC) from Sigma-Aldrich 
(Saint-Quentin Fallavier, France), Lipofectamine 2000 (LF 2000) from 
Invitrogen (Eragny sur Oise, France), high molecular weight hyaluronic acid 
(HA; 1,500,000 Da) from Fluka (Sigma Aldrich Chemie, Buchs, Switzerland). 
6.2.2 siRNAs 
SiRNA was obtained as single strands from Eurogentec (Seraing, Belgium). It 
was directed against a region between nucleotides 1523 and 1543 of the 
mRNA encoding for human telomerase reverse transcriptase (hTERT-mRNA; 
referred to transcript variant 1 of hTERT-mRNA; NCBI Entrez Nucleotide 
databank accession number: NM_198253). The sequence of the sense 
strand was 5’-GGAACACCAAGAAGUUCAUtt-3’ and the sequence of the 
antisense strand was 5’-AUGAACUUCUUGGUGUUCCtg-3’, where tt and tg 
are deoxynucleotides, respectively (anti-hTERT siRNA). Annealing of single 
strands was achieved according to the manufacturer’s recommendation in an 
annealing buffer containing 100 mM potassium acetate, 30 mM HEPES-KOH 
pH 7.4 and 2 mM magnesium acetate. A fluorescently labeled version of this 
siRNA was modified with 6-FAM at the 5’-ends. A nonsense siRNA was used 
as negative control. 
6.2.3 Radiolabeling of siRNA 
Radiolabeling of siRNA was performed by labeling the 5’-end of the sense 
strand with γ-33P-ATP (111 TBq/mmol; Perkin-Elmer Life Science, Mechelen, 
Belgium) catalyzed by T4 polynucleotide kinase (New England Biolabs, 
Frankfurt am Main, Germany) according to the manufacturer’s protocol. 
Labeled sense strand was purified by gel filtration using Bio-Gel P-6 Bio-Spin 
columns (Bio-Rad, Mitry Mory, France). Purity was proven by autoradiography 
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after gel electrophoresis of a sample on a 15% denaturing 7 M urea 
polyacrylamide gel. The labeled sense strand was annealed with the 
antisense strand as described above. 
6.2.4 Conjugation of DOPE to hyaluronic acid 
The conjugate of HA with DOPE was synthesized as reported by Surace et al. 
[144] based on a modified reaction described by Yerushalmi et al. [145]. In 
brief, 14 mg HA were dissolved in 5 ml water and preactivated for 2 hours at 
37°C by incubation with 6 mg EDAC at pH 4 which was adjusted by titration 
with 0.1 N HCl. Afterwards, DOPE suspension (360 µg) was added to the HA 
solution and pH was adjusted to 8.6 with 0.1 M borate buffer. The reaction 
was proceeded for 24 hours at 37°C. The conjugate was purified by 
ultrafiltration using a membrane with a molecular weight cut off of 100,000 Da 
(Amicon Ultrafiltration, Millipore, Billerica, MA, USA), lyophilized and stored at 
-25°C until further use. 
6.2.5 Preparation of liposomes 
DOTAP/DOPE liposomes were prepared by the ethanol injection method 
[146, 147]. DOTAP and DOPE were dissolved separately in chloroform of 
analytical grade (Carlo Erba Reagents, Val de Reuil, France). The solutions 
were mixed at the required amounts at a molar ratio of 1:1 and chloroform 
was evaporated under vacuum. Lipid films were stored under nitrogen at         
- 20 °C. For liposome preparation the lipid films were redissolved in absolute 
ethanol (analytical grade; Carlo Erba Reagents) at a concentration of 
10 mg/ml. For liposome preparation 50 µl of ethanolic lipid solution were 
rapidly injected into 1 ml filtered (0.22 µm) MilliQ water (Millipore, Guyancourt, 
France) under stirring with a magnetic bar to obtain a final lipid concentration 
of 500 µg/ml. HA-modified liposomes were prepared by diluting an aqueous 
stock solution of the HA-DOPE conjugate (1 mg/ml) to different concentrations 
in filtered MilliQ water before injection. The content of HA-DOPE conjugate is 
expressed in percent as wHA-DOPE/wtotal lipids x 100. For the removal of ethanol 
liposome suspensions were dialyzed against MilliQ water over night in 
Spectra/Por CE dialysis tubes with a molecular weight cut-off of 100,000 
(Spectrum Laboratories, Inc., Rancho Dominguez, CA, USA). 
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6.2.6 Preparation of lipoplexes 
Lipoplexes were prepared at different +/- ratios by rapidly injecting different 
volumes of 500 µg/ml liposome suspension in 2.5 µM siRNA solution. 
Suspensions were mixed thoroughly by pipetting up and down and incubated 
for 15 minutes at room temperature. Afterwards they were diluted with the 
respective medium to a final siRNA concentration of 100 nM. 
6.2.7 Characterization of liposomes and lipoplexes 
Liposomes and lipoplexes were characterized with regard to their size, size 
distribution and surface charge by dynamic light scattering and zeta potential 
measurement using a ZetaSizer Nano ZS (Malvern Instruments, 
Worcestershire, United Kingdom). Measurements were performed with 
50 µg/ml total lipids in filtered MilliQ water at 25°C using the standard settings 
of the instrument. Results are expressed as z-average (size), polydispersity 
index (PDI; size distribution) and zeta potential values (surface charge). All 
measurements were at least performed in triplicate. 
6.2.8 Binding efficiencies of lipoplexes 
Lipoplexes were prepared with radiolabeled siRNA at different +/- ratios as 
described above. The final siRNA concentration was 100 nM. Suspensions 
were submitted to ultracentrifugation using an Optima® LE-80K ultracentrifuge 
equipped with a type 50.4 Ti rotor (both Beckman-Coulter, Villepinte, France) 
at an average centrifugal force of 130,000 x g at 4°C under vacuum for 
1 hour. Binding efficiencies were determined by comparing the specific 
radioactivities of samples from the supernatant with samples taken before the 
centrifugation step. Experiments were performed in triplicate in MilliQ water 
and serum-free RPMI 1640 with GlutaMAXTM cell culture medium (Gibco, 
Paisley, UK). 
6.2.9 Colloidal stability of liposomes and lipoplexes in serum-free 
cell culture medium 
Lipoplexes of non-modified and 15% HA-DOPE at charge ratios of +/- 2:1 and 
+/- 8:1 were prepared as described above and diluted to 50 µg/ml total lipids 
with serum-free RPMI cell culture medium. Suspensions with liposomes only 
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were prepared accordingly but without siRNA. Changes in size were 
measured with the ZetaSizer Nano ZS (Malvern Instruments) at 25°C for two 
hours. The accuracy of measurements was verified by mixing each 
suspension thoroughly after each measurement to avoid false results that 
might be due to a quick sedimentation of agglomerates. All experiments were 
performed in triplicate. 
6.2.10 Protection of siRNA in lipoplexes in the presence of 
RNase V1 
Lipoplexes of non-modified and 15% HA-DOPE liposomes at +/- ratios of 2:1 
and 8:1 were prepared as described above with radiolabeled siRNA. 
Suspensions were diluted to 100 nM siRNA with RNase V1 (Ambion Applies 
Biosystems, Courtaboeuf, France) containing reaction buffer to a final ratio of 
0.1 U RNase V1 per 100 ng siRNA. Samples were incubated at 37°C for 
30 minutes. Afterwards RNase V1 activity was inhibited and lipoplexes were 
lysed using a mixture of 10% (w/v) sodium dodecylsulfate (SDS) and 5% (v/v) 
Triton X-100. All samples were kept on ice. After centrifugation at 10,000 x g 
and 4°C for 5 minutes samples from the supernatant were run on a 
12% non-denaturing polyacrylamide gel. The radiolabeled siRNA was 
visualized after gel drying by autoradiography. To verify that no degradation 
occurs during sample processing after incubation a post-incubation 
degradation control was included in the experiment: RNase V1 and siRNA 
were incubated separately and mixed only after addition of the SDS/Triton 
X-100 mixture to the RNase V1 solution. 
6.2.11 Stability of siRNA and lipoplexes in the presence of human 
serum 
Lipoplexes of non-modified and 15% HA-DOPE liposomes at +/- ratios of 2:1 
and 8:1 were prepared as described above with radiolabeled siRNA. 
Suspensions were diluted to 100 nM siRNA with RPMI cell culture medium 
(Gibco) containing different concentrations of human serum (Sigma, 
St. Quentin Fallavier, France) and incubated for 30 minutes at 37°C. 
Afterwards samples were run on a 12% non-denaturing polyacrylamide gel 
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without further lysis of lipoplexes. The radiolabeled siRNA was visualized after 
gel drying by autoradiography. 
6.2.12 Cell cultures and cell culture conditions 
The human lung cancer cell lines A549 and Calu-3 were obtained from 
American Type Culture Collection (ATCC-nos.: CCL-185 and HTB-55, 
respectively; Manassas, VA, USA). A549 cells were grown in RPMI 1640 with 
GlutaMAXTM cell culture medium (Gibco) supplemented with 10% fetal calf 
serum (Lonza, Verviers, Belgium) and 100 U penicillin/ 100 U streptomycin 
(Lonza). Calu-3 cells were grown in RPMI 1640 with GlutaMAXTM cell culture 
medium (Gibco) supplemented with 10% fetal calf serum (Lonza), 1 mM 
sodium pyruvate (Sigma) and 100 U penicillin/ 100 U streptomycin (Lonza). 
Cells were grown on 80 cm2 polystyrene cell culture flasks in an incubator at 
37°C, 5% CO2 and 90% humidity. Media were changed every other day and 
cells were subcultured once a week. 
6.2.13 Western blot analysis for the CD44 receptor 
Cells were washed with cold PBS and detached from the culture flask bottom 
by scrapping. Lysis was done after pelleting with a lysis buffer containing 1% 
Triton X-100, 50 mM Tris pH7.4, 150 mM sodium chloride, 1% deoxycholic 
acid, 0.1% sodium dodecylsulfate (SDS) and protease inhibitor cocktail 
(Complete Mini®, Roche, Mannheim, Germany). Protein concentrations were 
determined with the Bio-Rad Protein Assay (Bio-Rad Laboratories Inc., 
Marnes-la-Coquette, France). Protein samples were separated on a 8% 
denaturing SDS polyacrylamide gel and electroblotted to a Immobilo-P 
transfer membrane (Millipore). After blocking with 2% (w/v) bovine serum 
albumin (BSA) in 0.1% (v/v) Tween 20/PBS CD44 was detected by incubating 
the membrane with a 1:20 dilution of the monoclonal antibody Hermes I in 2% 
BSA/Tween 20/PBS (rat IgG2a; Department of Pathology, Stanford 
University, School of Medicine, Stanford, CA, USA) at 4°C over night. 
Hermes I was detected the next day using Vectastain Elite ABC kit anti-rat 
rabbit antibody IgG (Vector Laboratories, Inc., Berlingame, CA, USA) and 
Western Blotting Luminol Reagent (Santa Cruz Biotechnology, Inc., Santa 
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Cruz, CA, USA) on Amersham Hyperfilm ECL (GE Healthcare Ltd., 
Buckinghamshire, UK). 
6.2.14 Cytotoxicity tests 
For cytotoxicity tests A549 and Calu-3 cells were seeded on 96 flat bottom 
well plates at a density of 5,000 and 25,000 cells per well, respectively. Cells 
were incubated with different concentrations of non-modified and 15% 
HA-DOPE liposomes and their lipoplexes at +/- ratios of 2:1 and 8:1 in serum-
free RPMI cell culture medium without antibiotics for 3 hours under cell culture 
conditions. Lipoplexes of +/- 2:1 and +/- 8:1 corresponded to about 10 µg/ml 
and 50 µg/ml liposomes, respectively. Lipofectamine 2000 (LF 2000) was 
used for comparison. The required amount of LF 2000 was adjusted for the 
transfection of 100 nM siRNA as recommended by the manufacturer. This 
amount was regarded to be equal to the amount of lipids that is used for 
lipoplexes at the +/- ratio of 8:1. The different LF 2000 concentrations were 
adjusted accordingly. 
MTT cytotoxicity test 
Cells were incubated with different liposome concentrations and lipoplexes 
1 day after seeding. After three hours of incubation, the suspensions were 
replaced by the respective normal cell culture medium (see above). Cells 
were allowed to grown for another 48 hours under cell culture conditions. 
Afterwards 25 µl of a 5 mg/ml 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT; Sigma) in PBS were added to each well. Medium 
was removed after 2 hours of incubation under cell culture conditions and 
200 µl of pure dimethylsulfoxide (DMSO) was added to each well for cell 
lysis and dissolution of formazan crystals. Absorbance was measured at 
570 nm. Metabolic activity was as a measure for cell survival was calculated 
in comparison with non-treated cells according to the formula: (mean 
abstreated cells/ mean absnon-treated cells) x 100. Each concentration was measured 
in triplicate. 
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LDH cytotoxicity test 
Cells were incubated with different liposome concentrations and lipoplexes 
3 days after seeding. Liposome and lipoplex suspensions were prepared as 
described above but with phenol red- free RPMI cell culture medium (Gibco). 
After incubation for 3 hours, 100 µl samples from the supernatant of each well 
were taken and analyzed for LDH activity according to the manufacturer’s 
instructions of the Cytotoxicity Detection KitPlus (LDH) (Roche Diagnostics, 
Meylan, France). Absorbance was measured at 492 nm. LDH release from 
cells incubated with liposomes or lipoplexes was referred to the spontaneous 
LDH release from non-treated cells. Background controls for non-specific 
reactions included all incubation media without cells. Each concentration was 
measured in triplicates. 
6.2.15 Flow cytometry 
A549 and Calu-3 cells were seeded on 6 well plates at a density of 250,000 
cells per well. Lipoplexes were prepared as described above with 
FAM-labeled siRNA in serum-free RPMI cell culture medium. Cells were 
incubated with Lipoplexes of non-modified and 15% HA-DOPE liposomes at 
+/- ratios of 2:1 and 8:1 at a final siRNA concentration of 100 nM for three 
hours. Afterwards they were washed once with calcium and magnesium 
containing PBS (Ca/Mg-PBS; Gibco). Cells were detached with trypsin/EDTA 
(Lonza). After inactivation of trypsin with serum-free RPMI cell culture medium 
without phenol red, cells were pelleted and resuspended in PBS without 
calcium and magnesium. To be able to distinguish between internalized and 
extracellularly bound lipoplexes, half of the cells were incubated with 0.4% 
trypan blue in Ca/Mg-PBS and washed twice with normal PBS prior to 
trypsinization. Fluorescence intensities were measured using a FACSCalibur 
flow cytometer from Becton Dickinson (BD) Biosciences (Franklin Lakes, NJ 
USA) using the software CellQuestTM Pro Version 4.02 (BD Biosciences). The 
instrument was adjusted using non-treated cells. 
Chapter 6 - Hyaluronic Acid-Modified Liposomes for Targeted siRNA Delivery 
   
 112 
6.2.16 Determination of telomerase activity by the TRAP-qPCR 
assay 
A549 cells were seeded at a density of 100,000 and Calu-3 cells at 500,000 
cells per well on 6 well plates. One day after seeding cells were incubated 
with lipoplexes of non-modified and 15% HA-DOPE liposomes at +/- ratios of 
2:1 and 8:1 in serum-free RPMI cell culture medium at a final siRNA 
concentration of 100 nM for 3 hours. LF 2000 was used for comparison. 
Non-specific effects were examined with liposomes without siRNA and 
lipoplexes prepared with a nonsense sequence. 
Following incubation the medium was exchanged with normal cell culture 
medium and cells were kept under cell culture condition for further 48 hours. 
Afterwards, cells were washed once with cold PBS (4°C), detached by 
scrapping, pelleted and lysed in a non-denaturing lysis buffer (10 mM Tris-HCl 
pH 7.4, 1 mM magnesium chloride, 1 mM EGTA, 5 mM 
beta-mercaptoethanol, 1% Triton X100 and 10% glycerol). Protein 
concentrations were determined with the Bio-Rad Protein Assay (Bio-Rad 
Laboratories Inc., Marnes-la-Coquette, France). Telomerase activity was 
determined by the telomeric repeat amplification protocol (TRAP assay) 
adapted for quantitative real-time PCR (qPCR) [148, 149]. The protein 
concentration of each sample was adjusted to 100 ng/µl with lysis buffer. The 
TRAP-qPCR was performed with a LightCycler 1.5 (Roche Diagnostics, 
Meylan, France) using the LightCylcer FastStart DNA MasterPlus SYBR Green 
I kit (Roche Diagnostics, Meylan, France). The master mix was prepared 
according to the manufactures protocol. Each sample (20 µl) contained 
100 ng of protein extract, 100 ng TS primer (5’-AATCCGTCGAGCAGAGTT-3’) 
and 50 ng ACX primer (5’-GCGCGGCTTACCCTTACCCTTACCCTAACC-3’) [99] 
(both from Eurogentec, Seraing, Belgium). The TRAP-qPCR was run under 
the following conditions: 30 minutes at 30°C for the elongation of TS primer by 
telomerase; 10 minutes at 95°C for the inactivation of telomerase and 
activation of polymerase; amplification of telomerase products during 40 
cycles of 10 seconds at 95°C, 5 seconds at 62°C, 15 seconds at 72°C, final 
cooling step for 30 seconds at 40°C. Fluorescence intensities were acquired 
during amplification after each cycle. A calibration line was established by 
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serial dilution of protein extract from non-treated cells. The slope and 
y-intercept were determined after plotting log amount protein versus the cycle 
threshold value. Relative telomerase activity (RTA) was determined according 
to equation 6-1:  
! 
RTA = 10
Ctsample "Yintercept
slope
Equation 6-1 
 
where Ctsample is the cycle threshold value for the respective sample and 
Yintercept and slope are calculated from regression line [149]. RTAs of cells 
incubated with liposomes or lipoplexes were normalized to those of 
non-treated cells. 
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6.3 Results 
6.3.1 Properties of liposomes and lipoplexes 
The ethanol injection method allowed the preparation of nano-sized 
HA-DOPE modified liposomes with a conjugate content of up to 20% 
(wHA-DOPE/wtotal lipids). The sizes ranged from 110 to 160 nm. There was a 
gradual increase in size with increasing HA-DOPE content (Figure 6-1 A). 
Higher amounts of the conjugate resulted in the formation of agglomerates 
(data not shown). The size distribution of non-modified liposomes and 
liposomes with lower amounts of HA-DOPE (1 – 10%) was rather 
heterogeneous which was reflected by polydispersity indices (PDIs) of around 
0.4. This improved to values around 0.25 when 15 and 20% of conjugate were 
used (data not shown). Zeta potential values (ZPs) were in the range of +50 
to +60 mV for all liposome preparations at pH-values of about 6.5 (Figure 
6-1 A). 
The formation of complexes with siRNA at +/- charge ratios of 1:1 to 8:1 
resulted in lipoplexes with sizes around and below 200 nm and PDIs smaller 
than 0.25 for most of the preparations (Figure 6-1 B – F). The ZP 
measurements of lipoplexes clearly revealed the differences in the degree of 
liposome modifications. At the +/- ratio of 1:1 all lipoplexes were strongly 
negatively charged (≤ -40 mV; B). However, at +/- 2:1 lipoplexes prepared 
with non-modified liposomes were positively charged while ZPs decreased 
with increasing amounts of HA-DOPE for lipoplexes with modified liposomes 
(Figure 6-1 C). This trend was also observed at higher +/- ratios (Figure 
6-1 D-F). The pH values for lipoplexes were in the range of 6.5 to 7.0. 
Agglomeration occurred for lipoplexes in the range of -20 to +20 mV, 
demonstrating that electrostatic repulsion in this range is not sufficient to 
maintain the colloidal stability. 20% HA-DOPE liposomes were identified as a 
critical formulation because they formed agglomerates at +/- charge ratios of 
4:1, 6:1 and 8:1. 
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Figure 6-1: Properties of HA-modified DOTAP/DOPE liposomes prepared by the 
ethanol injection method. A: liposomes alone with different amounts of HA-DOPE 
conjugate (expressed in percent as (wHA-DOPE conjugate/wtotal lipids)*100) B-F: lipoplexes at 
varying +/- ratios with siRNA. Sizes for lipoplexes that formed agglomerates (agg.) 
were reduced to 500 nm for better representation. n ≥ 3 
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6.3.2 Binding of siRNA 
The binding experiments revealed that the modification of DOTAP/DOPE 
liposomes with the HA-DOPE conjugate did not compromise the binding 
efficiency of siRNA. In water as dispersion medium, almost complete binding 
was achieved at the +/- ratio of 2:1 for all preparations (Figure 6-2). 
Interestingly, with increasing +/- ratios the binding efficiency remained 
constant for lipoplexes prepared with higher HA-DOPE content, while it 
decreased slightly for non-modified liposomes and those with a lower 
HA-DOPE content. 
As partial conclusion from the results of liposome and lipoplex 
characterization and binding experiments, 15% HA-DOPE liposomes and the 
corresponding lipoplex preparations at charge ratios of +/- 2:1 (negative ZP) 
and +/- 8:1 (positive ZP) were chosen for further experiments. Non-modified 
liposomes and their respective lipoplexes were used for comparison. 
 
 
Figure 6-2: Binding efficiency of siRNA at different +/- ratios with different liposome 
preparations. The modification of DOTAP/DOPE liposomes with HA-DOPE does not 
influence the binding of siRNA. In serum-free cell culture medium binding of siRNA 
with HA-modified liposomes is even higher than with non-modified liposomes. n = 3 
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6.3.3 Influence of cell culture medium as dispersion medium 
All results reported so far were obtained from dispersions in MilliQ water. 
However, since cell culture experiments (see below) were performed in 
serum-free RPMI cell culture medium, its influence on liposome/lipoplex 
properties was further tested.  
As can be seen in Figure 6-2 the binding efficiency of HA-modified liposomes 
in cell culture medium decreased to about 85% for +/- 2:1 lipoplexes but was 
almost the same as in water for +/- 8:1. Again, in comparison with the 
non-modified liposomes, the modification did not compromise the binding 
efficiency. 
The effect of cell culture medium on the colloidal stability of liposomes and 
lipoplexes was tested in repeated measurements by dynamic light scattering 
over two hours. HA-modified liposomes alone agglomerated upon dispersion 
in cell culture medium almost immediately. In contrast, non-modified 
liposomes alone seemed to be more stable (Figure 6-3 A). However, in 
complex with siRNA at either ratio (+/- 2:1 and +/- 8:1) the HA-modified 
liposomes were stable over the time of the measurement while lipoplexes of 
non-modified liposomes quickly formed agglomerates (Figure 6-3 B). 
 
 
Figure 6-3 Colloidal stability of non-modified and HA-modified liposomes (A) and 
lipoplexes at +/- ratios of 2:1 and 8:1 (B) in serum-free cell culture medium measured 
over 2 hours by dynamic light scattering. Although non-modified liposomes appeared 
to be more stable than HA-modified liposomes both preparations tend to form 
agglomerates over time (A). In complex with siRNA HA-modified liposomes were stable 
while lipoplexes of non-modified liposomes quickly formed agglomerates. n = 3 
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6.3.4 Protection of siRNA in lipoplexes 
The exposure of lipoplexes to double-stranded RNA-degrading RNase V1 
revealed that the modification with HA-DOPE does not affect the protection of 
siRNA from degradation compared to non-modified lipoplexes (Figure 6-4 A). 
Only a slight degradation occurred for both preparations at either charge ratio 
(+/- 2:1 and +/- 8:1) and was not shown to be related to the treatment of 
lipoplexes after incubation. 
 
 
Figure 6-4: Protection of siRNA in complexes with either non-modified or HA-modified 
liposomes from degradation by RNase V1 (A) and human serum at different 
concentrations in cell culture medium (B). 1 = siRNA only; 2 = non-modified lipoplexes 
+/- 2:1; 3 = non-modified lipoplexes +/- 8:1; 4 = HA-modified lipoplexes +/- 2:1; 
5 = HA-modified lipoplexes +/- 8:1; C = post-incubation degradation control; W = siRNA 
in water. (A) The modification with HA-DOPE did not compromise the siRNA stability in 
complex. (B) The presence of serum even at high concentrations does not seem to 
influence the stability of lipoplexes prepared at a charge ratio of +/-8:1 of either 
non-modified or HA-modified lipoplexes. 
 
A similar result was observed when lipoplexes were dispersed in cell culture 
medium with different concentrations of human serum. In this experiment 
lipoplexes were not lysed after incubation but submitted directly to 
electrophoresis. This allows to investigate both the lipoplex stability and the 
protection of siRNA from degradation in the presence of human serum. The 
results show that even in 50% of serum lipoplex stability, and hence siRNA 
degradation, of HA-modified lipoplexes was comparable to non-modified 
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lipoplexes (Figure 6-4 B). One remarkable result was that lipoplexes at charge 
ratios of +/- 8:1 appeared to be significantly more stable in the presence of 
serum than under serum-free conditions. Using fluorescence microscopy and 
lipoplexes prepared with fluoresceinamine (FAM) - labeled siRNA at a charge 
ratio of +/- 8:1, it was verified that this observation was not due to the 
formation of large agglomerates that hinder a migration of siRNA. In contrast, 
non-modified lipoplexes in serum-free medium formed agglomerates that 
could be observed by microscopy (200 x magnification) while HA-modified did 
not, which is in good agreement with the size measurements shown in Figure 
6-3. However, in medium containing 50% of human serum no agglomeration 
for both kinds of preparations was observed (data not shown). 
6.3.5 Uptake of lipoplexes 
The uptake of lipoplexes prepared with fluorescently labeled siRNA into lung 
cancer cells was studied by flow cytometry with CD44-expressing A549 and 
CD44-deficient Calu-3 cells (western blot in Figure 6-5 A). As can be seen in 
Figure 6-5 B ii and iv, the incubation of CD44-positive A549 cells with 
HA-modified lipoplexes resulted in a shift to higher fluorescence values 
indicating a higher cell association and uptake compared to non-modified 
lipoplexes. Interestingly, the uptake was higher at the +/- ratio of 2:1 that at 
8:1. In contrast, such clear differences were not found for CD44-negative 
Calu-3 cells (Figure 6-5 B vi and vii). The incubation with LF2000 and siRNA 
resulted in a very heterogeneous uptake profile in both cell lines ranging from 
a population of non-transfected cells to cells that showed a very high uptake. 
Uptake profiles for cells treated with non-modified liposomes at either ratio 
were comparable, which demonstrates that the maximal transfection 
efficiency for this preparation is already reached at the +/- 2:1 ratio. 
Cells incubated with trypan blue prior to measurements to quench 
extracellular fluorescence showed comparable profiles that slightly shifted to 
lower intensity values (data not shown). 
Transfection was much more efficient in A549 cells than in Calu-3 cells for 
both HA-modified and non-modified liposomes. As can be seen in Table 6-1 
after quenching the extracellular fluorescence with trypan blue at least 75% of 
A549 cell took up the lipoplexes. Best results were obtained with HA-modified 
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lipoplexes at a +/- ratio of 2:1. In Calu-3 cells the highest uptake was also 
found for this preparation. But only about 30% of cells took up the lipoplexes. 
 
Table 6-1: Quantification of cells transfected with lipoplexes (compare Figure 6-5 B). 
Trypan blue – quenching was used to distinguish internalized lipoplexes from 
extracellularly bound lipoplexes. Uptake was considerably higher in A549 cells 
compared to Calu-3 cells. Best results were obtained for HA-modified liposomes at a 
+/- ratio of 2:1 with siRNA for both cell lines. 
 % of cells above fluorescence threshold 
 A549 Calu-3 
cells treated with: normal incubated with trypan blue normal 
incubated with 
trypan blue 
non-treated cells 0.4 - 0.8 - 
siRNA only 0.5 - 0.5 - 
non-modified  
liposomes +/- 2:1 92.0 76.5 37.8 20.4 
non-modified 
 liposomes +/- 8:1 92.6 73.8 35.8 18.5 
15% HA-DOPE 
liposomes +/- 2:1 99.5 92.6 47.9 30.1 
15% HA-DOPE  
liposomes +/- 8:1 96.7 79.7 34.2 15.1 
Lipofectamine 2000 70.2 72.7 40.9 33.8 
 
 
 
 
 
Next page: 
Figure 6-5: A: Detection of the CD44 receptor in A549 and Calu-3 lung cancer cells by 
western blot with the monoclonal antibody Hermes-I. A549 cells are CD44 positive 
while Calu-3 cells do not express this receptor. The faint band in the Calu-3 lane at 
about 72 kDa is due to a non-specific binding of the secondary antibody. B: Results 
from flow cytometry with A549 (i – iv) and Calu-3 (v – viii) cells after incubation with 
lipoplexes prepared with FAM-labeled siRNA. In contrast to CD44-negative Calu-3 cells 
(vi and vii) CD44-positive A549 cells showed a clear shift to higher fluorescence 
intensities for the HA-modified liposomes (ii and iii). Incubation with Lipofectamine 
2000 resulted in a very heterogeneous distribution for both cells cell lines (iv and viii). 
Incubation with siRNA alone did not increase the fluorescence intensities (i and v). 
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Figure 6-5 
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6.3.6 Cytotoxicity of liposomes and lipoplexes 
In the MTT (for metabolic activity) and LDH (for membrane integrity) assay 
both liposomal preparations without siRNA showed a cytotoxic effect in both 
cell lines at higher concentrations while LF 2000 only slightly reduced 
metabolic activity (MTT) and did not influence membrane permeability (LDH). 
In the LDH assay the treatment with 15% HA-DOPE liposomes resulted in a 
higher release of LDH than with non-modified liposomes. A549 cells appeared 
to be more sensitive than Calu-3 cells (Figure 6-6). However, no cytotoxicity 
was observed with lipoplexes of non-modified and HA-modified liposomes at 
+/- ratios of 2:1 (approx. 10 µg/ml lipids) and 8:1 (approx. 50 µl/ml lipids) as 
well as for LF 2000 + siRNA for both cell lines (Figure 6-6 B). 
 
Figure 6-6: A: MTT cytotoxicity assay with A549 and Calu-3 cells after treatment with 
non-modified and HA-modified liposomes and lipoplexes in comparison with 
Lipofectamine 2000. Measured values were referred to cells that were treated under the 
same conditions but without liposomes or lipoplexes. B: LDH release from A549 and 
Calu-3 cells after treatment with non-modified and HA-modified liposomes and 
lipoplexes in comparison with Lipofectamine 2000. The values are referred to the LDH 
release of cells that were treated under the same conditions but without liposomes or 
lipoplexes. Lipoplexes of +/- 2:1 and +/- 8:1 corresponded to about 10 µg/ml and 
50 µg/ml liposomes, respectively. Each concentration was measured in triplicate. 
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In the MTT assay the same was true for Calu-3 cells. However, for A549 cells 
there was a big difference between lipoplexes prepared with HA-modified 
liposomes and non-modified liposomes. The HA-modified lipoplexes were not 
cytotoxic while the treatment with non-modified lipoplexes resulted in a 
decrease of mitochondrial activity of about 40% for each preparation. When 
LF 2000 + siRNA was used an even stronger reduction in mitochondrial 
activity of about 60% was observed Figure 6-6 A). 
6.3.7 Inhibition of telomerase activity 
In A549 cells telomerase activity was successfully inhibited after a treatment 
with lipoplexes prepared with anti-hTERT siRNA (Figure 6-7). The reduction in 
telomerase activity was stronger for lipoplexes prepared at a +/- ratio of 8:1 
(15 – 20% of control) than 2:1 (25 – 30% of control). However, there was no 
longer any difference between HA-modified liposomes and non-modified 
liposomes. Also, treatment with lipoplexes containing the nonsense sequence 
and liposomes without siRNA at a concentration corresponding to the +/- ratio 
8:1 still exhibited a moderate (60-80% of control) reduction of telomerase 
activity. This effect was even more pronounced for preparations with 
non-modified liposomes. When LF 2000 was used as transfection reagent 
inhibition of telomerase activity by anti-hTERT siRNA was even stronger 
(about 10% of control), suggesting a significant contribution of direct inhibitory 
effects exerted by the transfection reagents. 
Calu-3 cells appeared to be less sensitive to the treatment with lipoplexes. 
Higher inhibition was obtained with HA-modified lipoplexes at a +/- ratio of 
8:1. However, telomerase activity was only reduced by maximally 50%. 
Non-specific reduction of telomerase activity was also found for liposomes 
alone and lipoplexes with nonsense siRNA, but they were less pronounced 
compared to A549 cells. Again, however, transfection with LF 2000 resulted in 
a similar, but still only moderate reduction in telomerase activity for no, 
non-sense and anti-hTERT siRNA. 
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Figure 6-7: Inhibition of telomerase activity in A549 and Calu-3 cells determined by the 
TRAP-qPCR assay after treatment with non-modified and HA-modified liposomes in 
comparison with Lipofectamine 2000. “+/- x:1 no siRNA” = cells were incubated with 
liposomes alone at the same concentrations used for the respective lipoplexes. 
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6.4 Discussion 
In our study, we demonstrated that cationic DOTAP/DOPE liposomes in a 
size range below 200 nm modified with the large negatively charged 
polysaccharide hyaluronic acid (HA) can be successfully prepared by the 
ethanol injection method. Surprisingly, zeta potential values of the 
HA-modified liposomes alone (Figure 6-1 A) did not differ from non-modified 
liposomes. Since the pKa-value for HA is about 3.0 and the pH-values for the 
different preparations were in the range of pH 6.5, a decrease of ZPs was 
expected with increasing concentrations of the HA-DOPE conjugate because 
of the negatively charged carboxylic groups of the polymer. However, the 
differences became apparent when complexes with siRNA were formed. The 
gradual decrease in zeta potential values for lipoplexes with +/- ratios ≥ 2:1 
with increasing amounts of the HA-DOPE conjugate demonstrates that HA is 
present on the surface (Figure 6-1 B – F).  
Although hyaluronic acid is a large negatively charged polymer that might 
interact with the positively charged liposomes, the modification was shown to 
have no negative influence on such important properties like the binding of 
siRNA, its protection in the complex from degradation by RNase V1 or 
complex stability in the presence of serum. On the contrary, binding of siRNA 
and especially the colloidal stability of HA-modified lipoplexes in serum-free 
cell culture medium were considerably improved compared to non-modified 
liposomes. These results indicate that i) despite the modification with HA the 
cationic liposome surface is still fully accessible for siRNA, which results in the 
high complexation efficiency and protection and ii) the modification might be 
regarded as a stabilizer comparable to polyethylene glycol [150]. Peer and 
Margalit reported in their experiments with neutral liposomes a prolonged 
systemic circulation in mice, which they attributed to a “hydrophilic coat effect” 
due to the modification with HA [138, 139]. The presence of the negatively 
charged polymer on the liposomes might reduce the interaction with counter 
ions from the solution. Additionally, a steric repulsion between the vesicles 
seems to be very likely. 
The modification also improved the cytotoxic profile of DOTAP/DOPE 
liposomes. As could be shown in the MTT and LDH assay with A549 cells, 
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lipoplexes prepared with HA-modified liposomes strongly reduced the toxicity 
compared to lipoplexes prepared with non-modified liposomes or LF 2000. 
Since HA is endogenous to the human body and therefore fully biocompatible, 
the presence of the polymer on the liposome surface might avoid the direct 
contact of the cationic liposome with the negatively charged cell surface and 
hence reduce their cytotoxic potential. 
In our uptake studies we were able to demonstrate that the HA-modified 
liposomes considerably improve the uptake of lipoplexes into 
CD44-expressing A549 lung cancer cells compared to non-modified 
liposomes and that this difference was not found for CD44-deficient Calu-3 
cells (Figure 6-5 B and Table 6-1). However, the uptake of HA-modified 
lipoplexes in A549 cells at the +/- ratio 8:1 was lower compared to +/- 2:1. In 
the latter case, the loading of siRNA per lipoplex was reduced because of the 
increased liposome concentration. Zeta potential measurements 
demonstrated that at +/- 2:1 the surface charge of lipoplexes is strongly 
negative (about -35 mV), indicating an excess of siRNA on the liposomal 
surface (Figure 6-1 C). At +/- 8:1 the surface charge is positve (about 
+25 mV), which shows that the liposome surface is not fully covered. Since 
the siRNA concentration was kept constant at 100 nM throughout the 
experiments, the +/- 8:1 preparation contained an increased concentration of 
lipoplexes with reduced siRNA content compared to the +/- 2:1 preparation 
with higher siRNA loading and lower total lipoplex concentration. Given that 
both preparations were used under the same conditions and that the uptake 
of HA-modified liposomes via interaction with the CD44 receptor is a saturable 
process [151], +/- 2:1 complexes were more efficient. 
The results from the uptake studies, however, were not consistent with the 
measurements of the TRAP assay. Although telomerase activity was reduced 
in transfected A549 cells, and to a lesser extend also in Calu-3 cells, the 
expected difference between non-modified and HA-modified liposomes was 
not found. This result can most likely be attributed to some non-specific 
effects exerted by the lipidic transfection agents and the siRNA concentration 
used in these experiments. Since siRNA has been reported to be able to 
induce concentration-dependent activation of the interferon system [152] and 
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changes in the levels of non-targeted proteins [153, 154], especially in 
combination with cationic lipids [155], further studies regarding the use of 
cationic lipids for siRNA-transfection and gene silencing as well as an 
optimization of siRNA concentrations appear to be necessary. 
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6.5 Conclusion 
We successfully prepared cationic DOTAP/DOPE liposomes modified with the 
large negatively charged polymer hyaluronic acid as nano-sized carriers for 
siRNA. This modification did not influence the capability of the DOTAP/DOPE 
liposomes to efficiently bind and protect siRNA. On the contrary, it significantly 
improved such important properties like stability in high-salt cell culture 
medium, reduced cytotoxicity and allowed the targeting of CD44-expressing 
lung cancer cells. Our results are an encouraging starting point for further 
in vitro and in vivo studies where the efficacy of this system will be tested. 
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Chapter 7  
Summary and Outlook 
The work presented in this thesis dealt with three different strategies for the 
treatment of non-small lung cancer by telomerase inhibition. In this context 
important steps in the preclinical evaluation of new drug substances and drug 
carrier systems based on cell culture models were investigated. 
The results from the characterization of the potential drug candidate and 
model substance BRACO19 are important for future studies like animal 
experiments or clinical trials. Problems like therapy failure that might occur 
during such investigations can be explained by the findings described in this 
dissertation. Our results demonstrate that an appropriate formulation is 
required for BRACO19 and related substances to improve its permeability 
across biological barriers and prevent the rapid decomposition in physiological 
media. 
The oligonucleotide-based telomerase inhibitors 2OMR and siRNA are 
promising candidates that might be used in drugs of the next generation. The 
strategies presented here for their (targeted) delivery into lung cancer cells 
are an important step towards their therapeutic application. Since the 
problems of their poor uptake and stability have been extensively described in 
the literature, our studies were focused on the characterization and 
optimization of potential carrier systems to improve the uptake and reduce 
inactivation due to an early degradation. 
The work with the cationic chitosan/PLGA nanoparticles as a carrier system 
for 2OMR demonstrated the necessity for an accurate optimization of the 
particle formulation for further studies. Particle properties strongly depended 
on the ratio of the anionic polymer PLGA and the cationic polymer chitosan. 
The simple criterion “cationic particles improve the uptake” is not applicable 
for the combination of these two polymers. As could be shown by the 
experiments a certain amount of chitosan in the particle preparation is 
required for the optimal uptake of 2OMR into lung cancer cells. Since an 
increase of the chitosan concentration did not result in further uptake 
improvements the optimum formulation for chitosan/PLGA nanoparticles has 
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been found. Another important result of these experiments was that 
nanoplexes were almost only taken up by lung cancer cells and not by 
non-malignant cells although they were not specifically modified for the 
targeting of this cell type. This indicates that a treatment with nanoplexes of 
2OMR and chitosan/PLGA nanoparticles does not affect healthy cells. 
Together with the specific inhibition of telomerase activity, side effects in such 
a therapeutic approach should be reduced to a minimum. 
The strategy of a targeted uptake of nano-sized surface modified carrier 
systems into lung cancer cells was employed for the delivery of siRNA via 
hyaluronic acid modified cationic liposomes. This targeting was intended to 
improve the uptake of lipoplexes into tumors that overexpress the CD44 
receptor. In these studies the optimization of the liposome formulation was 
also an important prerequisite for further experiments. Since the large polymer 
hyaluronic acid is negatively charged under physiological conditions, one 
major concern was that the preparation of modified cationic liposomes is not 
easily feasible. However, the binding and stability experiments revealed that 
these concerns were not justified. The modified liposomes were as efficient in 
binding siRNA as non-modified liposomes and showed an improved stability 
in physiological cell culture medium and a reduced cytotoxicity. The aim of 
targeting CD44-expressing lung cancer cells was successfully accomplished. 
The results from these experiments are a good basis for further studies with 
this kind of modified siRNA carrier system. 
 
In summary, the inhibition of telomerase activity via siRNA appears to be the 
most promising strategy for the treatment of non-small cell lung cancer by 
telomerase inhibition. 
BRACO19’s mechanism, the induction of dysfunctional telomeres by 
G-quadruplex stabilization, is a new and interesting approach for cancer 
treatment. However, it has to be considered that this molecule and other 
substances with the same mechanism are not selective for telomeres but can 
also bind to other guanine-rich regions of the DNA that form G-quadruplex 
structures [52]. Even if the problems described in Chapters 2 and 3 might be 
solved by suitable formulations of the drug, the effects of binding to DNA 
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regions other than the telomeres still needs to be addressed to learn more 
about possible unwanted side effects. Also, it still needs to be clarified how 
the induced telomere dysfunction affects healthy cell types like stem cells or 
germ cells that have a high proliferative capacity. 
The strategy of telomerase inhibition using oligonucleotides should be 
preferred because they allow the design of highly specific and selective 
sequences. Therefore, unwanted side effects can most probably be reduced 
to a minimum. Regarding the work described here, siRNA is the more 
promising approach because of two reasons: 
i) siRNA does not have to enter the nucleus of a cell to be effective but 
only needs to be released into the cytoplasm after transfection. In 
comparison with 2OMR, which has to reach the nucleus to bind to the 
template region of hTR, siRNA has one barrier less to overcome. 
ii) siRNA is effective at much lower concentrations than 2OMR. The factor 
for the experiments presented here is 40 (4 µM 2OMR vs. 0.1 µM 
siRNA). Considering values from literature, this factor could even be 
increased to 100 to 1000 with a highly specific sequence under 
optimized conditions. With regard to a possible therapeutic application in 
humans a treatment with siRNA would require less oligonucleotides and 
less of the carrier system than 2OMR. 
For the continuation of this project with siRNA as an inhibitor of telomerase 
activity the following steps need to be considered. 
First a screening of several siRNA sequences is necessary to identify the one 
with the highest selectivity and inhibitory potential, followed by an optimization 
of siRNA concentrations to avoid non-specific effects on protein biosynthesis 
as observed in these experiments. Afterwards the carrier system has to be 
optimized to reduce non-specific effects on telomerase activity and to avoid 
cytotoxicity at higher concentrations. The carrier should also be suitable for an 
application as an aerosol, to fulfill the final aim of the project of an inhalative 
treatment of lung cancer. 
Additionally, the test systems have to be changed or extended. In all parts of 
this thesis in vitro cell culture models, either derived from tumor or 
non-malignant tissue, were an essential part to investigate the new strategies. 
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Cell culture models are suitable systems to provide information about 
processes that occur at the site of interest. However, it has to be kept in mind 
that these models are only able to simulate the situation when the drug 
substance or the drug loaded carrier system reached the target tissue. To 
learn more about the distribution, uptake or efficacy of the preparation, further 
studies should include more complex models like the isolated perfused lung or 
animal experiments. 
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Chapter 8  
Zusammenfassung und Ausblick 
Im Rahmen der hier vorgestellten Doktorarbeit wurden drei verschiedene 
Strategien zur Therapie des nicht-kleinzelligen Lungenkarzinoms mit 
Telomeraseinhibitoren behandelt. Hierbei wurden wichtige Phasen der 
präklinischen Erprobung neuer Wirkstoffe und Wirkstoffträgersyteme auf 
Basis von Zellkulturmodellen durchschritten. 
Die Daten, die bei der Charakterisierung des potentiellen Wirkstoffkandidaten, 
bzw. der Modellsubstanz, BRACO19 erhalten wurden stellen wichtige 
Informationen für das weitere Verständnis von eventuelle auftretenden 
Problemen in späteren Phasen seiner Erprobung in Tierversuchen oder 
klinischen Studien dar. Die vorliegenden Ergebnisse zeigen deutlich, dass für 
eine weitere Erprobung von BRACO19 oder von seiner Struktur abgeleiteten 
Substanzen der Einfluss der Formulierung eine große Rolle spielen wird, um 
die aufgezeigten Probleme der sehr schlechten Permeabilität und raschen 
Zersetzung zu umgehen. 
Die Oligonukleotid-basierten Wirkstoffe 2OMR und siRNA sind viel 
versprechende Substanzen, die in Arzneimitteln der nächsten Generation zur 
Anwendung kommen könnten. Die hier vorgestellten Strategien zur 
Verbesserung der (gezielten) Aufnahme in Lungenkrebszellen sind ein 
wichtiger Schritt in Richtung ihrer therapeutischen Verwendung. Da die 
Problematik mit Hinblick auf ihre Aufnahme- und Stabilitätseigenschaften 
bereits ausführlich in der Literatur beschrieben wurde, lag der Schwerpunkt 
der hier vorgestellten Arbeiten auf der Charakterisierung und Optimierung 
möglicher Trägersysteme, die die Aufnahme in die Zellen verbessern und 
eine frühzeitige Inaktivierung durch Abbau verhindern. 
Bei den kationischen Chitosan/PLGA Nanopartikeln als Trägersystem für die 
2OMR zeigte sich die Notwendigkeit einer sorgfältigen Optimierung der 
Formulierung für weitere Arbeiten. Die Kombination aus dem anionischen 
Polymer PLGA und dem kationischen Polymer Chitosan führt je nach 
Mengenverhältnissen zu Partikeln mit unterschiedlichen Eigenschaften. Das 
einfache Kriterium “kationische Partikel führen zur Aufnahmeverbesserung” ist 
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bei der Verwendung dieser zwei Polymersorten nicht ausreichend. Wie die 
Versuche zeigten, ist zunächst eine gewisse Menge an Chitosan in der 
Partikelzubereitung notwendig, um eine größtmögliche Aufnahme von 2OMR 
in Lungenkrebszellen zu erreichen. Das eine weitere Steigerung der 
Chitosankonzentration jedoch nicht in einer weiteren Aufnahmeerhöhung 
resultiert, deutet darauf hin, dass die optimale Partikelformulierung gefunden 
wurde. Ein weiteres wichtiges Ergebnis dieser Versuche war die Erkenntnis, 
dass die Nanoplexe fast nur in Krebszellen aufgenommen wurden, obwohl sie 
nicht speziell modifiziert waren, um diesem Zelltyp gezielt zu erkennen. Dies 
lässt darauf schließen, dass normale, gesunde Zellen von einer Behandlung 
mit den 2OMR-Chitosan/PLGA-Nanoplexen wenig beeinflusst werden dürften 
und Nebenwirkungen, die durch die Verwendung des spezifischen 
Telomeraseinhibitors bereits gering sein sollten, auf ein Minimum reduziert 
werden. 
Die Strategie der gezielten Aufnahme nanoskaliger oberflächenmodifizierter 
Trägersysteme in Krebszellen wurde für das Delivery von siRNA mittels 
Hyaluronsäure modifizierten kationischen Liposomen verfolgt. Dieses 
Targeting soll eine verstärkte Aufnahme der Lipoplexe in Tumore 
gewährleisten, die den CD44-Rezeptor überexprimieren. Somit können 
höhere Wirkstoffkonzentrationen im erkrankten Gewebe erreicht werden und 
gesundes Gewebe bleibt möglichst von der Therapie verschont. Auch hier 
war die Optimierung der Formulierung zunächst eine wichtige Voraussetzung 
für weitere Versuche. Da Hyaluronsäure unter physiologischen Bedingungen 
ein negativ geladenes Polymer ist, war zu befürchten, dass eine Modifizierung 
der verwendeten kationischen DOTAP/DOPE Liposomen nicht ohne weiteres 
möglich ist. Die Bindungs- und Stabilitätsversuche ergaben aber, dass diese 
Befürchtungen unbegründet waren. Die modifizierten Liposomen zeigten die 
gleiche Bindungseffizienz wie nicht modifizierte Liposomen und wiesen 
darüber hinaus eine höhere Stabilität in physiologischen Zellkulturmedium auf 
sowie eine reduzierte Zytotoxizität. Das Ziel der verbesserten 
Aufnahmeeffizienz von siRNA in CD44-überexprimierende Lungenkrebszellen 
durch die Modifizierung der Liposomen mit Hyaluronsäure wurde erreicht und 
muss nun in weiteren Versuchen hinsichtlich seiner Wirkung getestet werden. 
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Zusammenfassend betrachtet stellt die siRNA-basierte Strategie zur 
Behandlung von Lunkenkrebs mit Telomeraseinhibitoren die 
vielversprechendste Variante dar. 
Der Wirkmechanismus von BRACO19 über die G-Quadruplexstabilisierung 
bis zu dysfunktionalen Telomeren ist ein neuer interessanter Weg zur 
Behandlung von Krebs. Allerdings muss man hierbei beachten, dass diese 
Substanzklasse nicht selektiv auf Telomere ausgerichtet ist, sondern auch in 
anderen Guanin-reichen Regionen der DNA, in denen sich G-Quadruplex-
Strukturen bilden können [52], binden kann. Selbst wenn die in Kapitel 2 und 
3 beschriebenen Probleme durch galenischen Maßnahmen umgangen 
werden, gilt es abzuklären, in wie weit diese Vorgehensweise durch Bindung 
des Wirkstoffs in anderen Bereichen als Telomere zu eventuellen 
unerwünschten Wirkungen führt. Außerdem muss gründlich untersucht 
werden, wie sich die herbeigeführte Telomerdysfunktion auf andere häufig 
teilende Zelltypen, wie zum Beispiel Keimzellen oder Stammzellen, auswirkt. 
Die Strategie der Telomerasehemmung mit Hilfe von Oligonukleotiden ist 
vorzuziehen, weil durch eine sorgfältige Sequenzauswahl eine hohe Spezifität 
und Selektivität gegeben ist, was die Gefahr von möglichen unerwünschten 
Wirkungen stark reduziert. Die siRNA ist dabei aus folgenden zwei Gründen 
der aussichtsreichere Kandidat: 
i) siRNA muss zur Entfaltung ihrer Wirkung nicht in den Zellkern gelangen. 
Die Freisetzung aus dem Trägersystem in das Zytoplasma ist hierfür 
ausreichend. Damit besteht für diese Vorgehensweise eine Barriere 
weniger im Vergleich zur 2OMR, die bis in den Zellkern gelangen muss, 
um an die Template Region der hTR zu binden. 
ii) siRNA ist in wesentlich geringeren Konzentrationen wirksam als 2OMR. 
Der Faktor in den hier durchgeführten Versuchen beträgt 40 (4 µM 
2OMR vs. 0,1 µM siRNA). Ein Blick in die Literatur zeigt, dass dieser 
Faktor bei Auswahl einer hochspezifischen Sequenz unter optimierten 
Bedingungen auf 100 bis 1000 erhöht werden kann. Im Umkehrschluss 
bedeutet dies mit Hinblick auf eine mögliche Anwendung am Menschen, 
dass geringere Konzentrationen an siRNA und Trägersystem zum 
Einsatz kommen würden. 
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Zur Fortführung des Projektes mit siRNA zur Telomerasehemmung sollte in 
folgenden Schritten vorgegangen werden. 
Zuerst ist ein Screening weiterer siRNA Sequenzen nötig um diejenige mit der 
größten Selektivität und Hemmeffizienz zu identifizieren. Anschließend muss 
die Konzentration so optimiert werden, dass unspezifische Effekte auf die 
Proteinbiosythese, wie sie in den hier beschriebenen Versuchen beobachtet 
wurden, vermieden werden. Das Trägersystem sollte dahingehend optimiert 
werden, dass keine Effekte auf die Telomeraseaktivität zu finden sind und 
auch bei höheren Konzentrationen keine Toxizität auftritt. Außerdem sollte es 
so ausgelegt sein, dass eine Überführung in ein Aerosol möglich ist, um das 
Ziel der Studien der inhalativen Applikation zu erreichen. 
Zusätzlich müssen die Testsysteme verändert bzw. erweitert werden. In allen 
Teilen dieser Arbeit war die Verwendung von in vitro Zellkulturmodellen, die 
sich entweder aus Tumor- oder nicht malignen Gewebe ableiteten, ein 
wichtiger Bestandteil zur Untersuchung der vorgestellten Strategien. Diese 
Zellkulturmodelle lieferten gute Informationen zum Verständnis im 
betrachteten Zielgewebe. Hierbei muss jedoch beachtet werden, dass die 
Modelle nur Momentanaufnahmen darstellen, die diejenigen Zustände 
simulieren, wenn der Wirkstoff, bzw. das mit Wirkstoff beladenen 
Trägersystem das Zielgewebe erreicht hat. In den weiterführenden Studien ist 
daher zur Erlangung tiefer greifender Information über die Verteilung, 
Aufnahme und Wirksamkeit der Zubereitung die Verwendung von 
komplexeren Modellen, wie zum Beispiel die isoliert perfundierten Lunge oder 
der Tierversuch, notwendig. 
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Abbreviations 
  
2OMR 2’-O-methyl-RNA 
AB apical to basolateral direction (in transport studies) 
ALT alternative lengthening of telomeres 
ATCC American Type Culture Collection 
BA basolateral to apical direction (in transport studies) 
BSA bovine serum albumin 
BSS balanced salt solution 
CPNP chitosan/PLGA nanoparticles 
DiI 1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate 
DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane 
FAM carboxyfluoresceinamine 
FCS fetal calf serum 
HA hyaluronic acid 
hAEpC primary human alveolar epithelial cells 
HBSS Hank’s balanced salt solution 
HSA human serum albumin 
hTERT human telomerase reverse transcriptase 
hTR human telomerase RNA 
IAM immobilized artificial membrane 
LDH lactate dehydrogenase 
LF 2000 Lipofectamine 2000® 
MTT methyl-thiazolyl-tetrazolium 
NEAA non-essential amino acids 
NSCLC non-small cell lung cancer 
PBS phosphate buffered saline 
PDI polydispersity index 
PLGA poly(lactic-co-glycolic acid) 
PVA polyvinyl alcohol 
RNAi RNA interference 
SAGM small airway growth medium 
SCLC small cell lung cancer 
SDS sodium dodecylsulfate 
SEC size exclusion chromatography 
siRNA small interfering RNA 
TEAC tetraethylammonium chloride 
TEER transepithelial electrical resistance 
TNM classification of malignant tumors; T = tumor size, N = involvement of 
regional lymph nodes, M = distant metastasis 
TRAP telomeric repeat amplification protocol 
ZP zeta potential 
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